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Abstract 
 
Background: Children with hearing loss associated with otitis media with effusion (OME) are 
commonly managed by surgical intervention, hearing aids, or watchful waiting. A safe, 
inexpensive, effective medical treatment would enhance treatment options. Small, poorly 
conducted trials have found short term benefit from oral steroids.  
Objective: To determine the clinical and cost effectiveness of a 7-day course of oral steroid 
on improving hearing at 5 weeks in children with persistent OME symptoms and current 
bilateral OME and hearing loss demonstrated by audiometry.  
Design: Double-blinded, individually randomised placebo-controlled trial. 
Setting: Ear, Nose and Throat outpatient (ENT) or Paediatric Audiology and Audiovestibular 
Medicine (AVM) clinics in Wales and England.  
Participants: Children aged 2 to 8 years with symptoms of hearing loss attributable to OME 
for at least 3 months, a diagnosis of bilateral OME made on the day of recruitment, and 
audiometry confirming hearing loss.  
Interventions: 7-day course of oral soluble Prednisolone, as a single daily dose of 20mg for 
children aged 2-5 years or 30mg for 6-8 year olds, or matched placebo. 
Main outcome measures: Acceptable hearing at 5 weeks from randomisation. Secondary 
outcomes included acceptable hearing at 6 and 12 months, tympanometry, otoscopic findings, 
healthcare consultations related to OME and other resource use, proportion who had 
ventilation tube (grommet) surgery at 6 and 12 months, adverse effects, symptoms, functional 
health status, health related quality of life (HRQoL), short and longer term cost effectiveness. 
Results A total of 389 children were randomised. Satisfactory hearing at 5 weeks was 
achieved by 39.9% and 32.8% in the oral steroid and placebo groups respectively (absolute 
difference of 7.1 (95% CI: -2.8 to 16.8%), Number needed to treat (NNT) = 14). This 
difference was not statistically significant. Secondary outcomes were consistent with the 
picture of a small or no benefit, and we found no subgroups who achieved a meaningful 
benefit from oral steroids. The economic analysis showed that treatment with oral steroids 
was more expensive and accrued fewer quality adjusted life years (QALYS). However, 
differences were small and not statistically significant, and sensitivity analyses demonstrated 
large variation in results. 
Limitations The trial was adequately powered to detect a 15% difference in recovery at 5 
weeks, however, more children than anticipated recovered by 5 weeks spontaneously leading 
to the possibility of a Type II error. 
xii 
 
Conclusions: OME in children with documented hearing loss and attributable symptoms for 
at least three months has a high rate of spontaneous resolution.  Discussions about watchful 
waiting and other interventions will be enhanced by this evidence. Our findings suggest that 
any benefit from a short course of oral steroids for OME is likely to be small and of 
questionable clinical significance, and unlikely to be cost-effective, and therefore we cannot 
recommend their use. 
Future work: Studies exploring optimal approaches to sharing natural history making and 
enhancing shared decision making in this area are needed.  
Trial registration: EudraCT number: 2012-005123-32 and ISRCTN: ISRCTN49798431 
(Registered 7 December 2012). 
Funding details: This project was funded by the NIHR Health Technology Assessment 
programme (project number 11/01/26). 
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Plain English Summary 
 
Glue ear (also known as otitis media with effusion) is a condition where fluid builds up 
behind the ear drum. It is very common in children and is the most common reason for 
children to have bad hearing. Most glue ear gets better with time, but some children have bad 
hearing from glue ear for many months, and this can affect learning, behaviour, language and 
mood. Very few treatments have been found to help glue ear. Many children have an 
operation (grommet surgery), but this involves a general anaesthetic and sometimes only 
works for a short period. Steroid tablets are often used to treat conditions such as asthma in 
children. Some studies have found that steroids may help glue ear to get better, but the 
previous studies gave different results, and were not good quality.  
 
The OSTRICH trial set out to see if steroid tablets would help improve hearing in children 
with glue ear, in both ears, who have had this for three months or more as well as proven 
hearing loss. Children were given steroid tablets or dummy (placebo) tablets for one week 
and had their hearing assessed four weeks after treatment, and again after six and twelve 
months. Around one in three children had good hearing four weeks after treatment and this 
had increased to around half of the children after 6 months. Slightly more children who had 
been given steroids developed good hearing, but the difference was small and could be due to 
chance. We found no differences between groups in symptoms, grommet operations, visits to 
the doctor or quality of life. 
 
These findings suggest that lots of children with glue ear that has lasted three months or more 
will get better with time, and that taking steroid tablets does not help hearing get better more 
quickly.   
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Scientific Summary 
 
Background 
Otitis media with effusion (OME) affects up to 80% of children by 4 years of age and is the 
commonest cause of hearing loss in children in the UK. Most episodes resolve spontaneously, 
but 5% of preschool age children have bilateral hearing loss from OME that lasts 3 months or 
longer. Significant hearing loss can affect mood, communication, concentration, learning, 
socialisation, language development and family function. Antibiotics, topical intranasal 
steroids, decongestants, antihistamines and mucolytics have all been shown to be ineffective 
treatments for OME. Use of an auto-inflation (AI) device benefits some 4 to 11 year olds 
with OME. However, OME is most prevalent, and has most impact on language 
development, in children who are generally too young to use an AI device. Management 
options are therefore largely limited to watchful waiting, hearing aids, or surgical insertion of 
ventilation tubes (grommet surgery) through the tympanic membrane (with or without 
adenoidectomy or tonsillectomy), and OME remains the commonest reason for childhood 
surgery in the UK.  
 
A Cochrane review on oral or topical steroids for OME found a statistically significant 
benefit from oral steroids plus antibiotics versus antibiotics alone for OME and a trend 
towards a significant benefit for oral steroids versus placebo. Studies were generally of poor 
quality, short term and under-powered. 
 
Objectives 
The primary objective was to determine the clinical and cost effectiveness of a 7-day course 
of oral steroid on improving hearing at 5 weeks in children with persistent OME symptoms 
and current bilateral OME and hearing loss demonstrated by audiometry. Secondary 
objectives include assessing the longer-term (at 6 months and 12 months) effects of a course 
of oral steroids on hearing, OME (assessed via tympanometry and otoscopy), healthcare 
consultations, insertion of ventilation  tubes, adverse effects, symptoms, functional health 
status, health related quality of life (HRQoL), and to assess the cost effectiveness. 
 
 
 
Methods 
xv 
 
This was a double-blind, individually randomised, placebo-controlled trial with participants 
identified and followed up in Ear, Nose and Throat (ENT) outpatient or Paediatric Audiology 
and Audiovestibular Medicine (AVM) clinics in Wales and England.1 Trial sites were 
selected on the basis of their recruitment potential and being part of a clinical research 
network. 
 
Eligible participants were children aged 2 to 8 years with symptoms of hearing loss 
attributable to OME for at least 3 months, a diagnosis of bilateral OME made on the day of 
recruitment, and audiometry confirming hearing loss (more than 20 decibels hearing level 
(dBHL)) averaged within the frequencies of 0.5, 1, 2 and 4 kilohertz (KHz) in both ears by 
pure tone audiometry (PTA), visual reinforcement audiometry (VRA) or ear specific play 
audiometry, or more than 25 dBHL averaged within the frequencies of 0.5, 1, 2, and 4 KHz 
by soundfield VRA or soundfield performance/play audiometry in the better hearing ear on 
the day of recruitment or within the preceding 14 days. Exclusion criteria included current 
systemic infection or acute ear infection, cleft palate, Down’s syndrome, chronic co-morbid 
illness (e.g. diabetes mellitus, renal failure, heart failure), current known sensory hearing loss, 
oral steroids taken in the preceding 4 weeks, and having a condition that increases their risk 
of adverse effects from oral steroids. 
 
Participants were randomised (1:1) using random permuted blocks stratified by site and 
child’s age, to a 7-day course of oral soluble Prednisolone as a single daily dose (20mg for 
children aged 2-5 years or 30mg for 6-8 year olds) or matched placebo. The primary outcome 
was acceptable hearing at 5 weeks from randomisation (4 weeks after conclusion of 
treatment), defined as ‘less than or equal to 20 dBHL’ averaged within the frequencies of 0.5, 
1, 2 and 4 kHz in at least one ear in children assessed by PTA, ear specific insert VRA or ear 
specific play audiometry, and ‘less than or equal to 25 dBHL’ averaged within the 
frequencies of 0.5, 1, 2 and 4 KHz in children assessed by soundfield VRA or soundfield 
performance/play audiometry. Secondary outcomes include longer-term (6 and 12 month) 
hearing, evidence of OME (by otoscopy and tympanometry), healthcare consultations for 
OME, ventilation tube surgery,  adverse effects, symptoms, functional health status (OM8-
30), health related quality of life (Pediatric Quality of Life Inventory (PedsQL)) and health 
utilities (Health Utilities Index Mark 3 (HUI3)). 
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Baseline data were collected by the recruiting clinician and study nurses. A parent/legal 
guardian was asked to complete a questionnaire booklet that included the OM8-30, the 
PedsQL, and the HUI3. If appropriate, a child’s version of the questionnaire booklet was also 
completed by the participant, comprising the child self-report version of PedsQL. 
Parents/legal guardians were asked to complete a diary at home over the first 5 weeks. The 
diary was completed daily in the first week to record treatment adherence. Thereafter, it was 
completed weekly for 4 weeks to record symptoms, adverse events, and healthcare resource 
use, additional medication taken, time off school/nursery and parental time off work. Follow-
up assessments were conducted at week 5 (4 weeks’ post completion of treatment), 6, and 12 
months, where completion of the questionnaire booklets and the clinical assessments (e.g. 
audiometry, tympanometry and otoscopy) were repeated as well as questions about use of 
NHS resources, additional medication taken, time off school/nursery and parental time off 
work. Although the follow-up of participants continued for 12 months, after the 5-week 
assessment, all participants resumed ‘usual care’. 
 
We required 302 participants to demonstrate a change in the proportion of children with 
resolved hearing loss at 5 weeks’ post randomisation from 20% in a control group to 35% in 
an intervention group with 80% power at a 5% significance level. We selected a conservative 
estimate of 1.75 for our effect size (ratio of proportions) because we considered that a 15% 
absolute increase in the rate of resolution at 5 weeks would represent a clinically meaningful 
benefit that could result in a meaningful reduction in operations. 
 
The primary analyses were by intention to treat (ITT) using a multilevel logistic regression 
model, adjusting for site, child’s age, and time to follow up with comparisons presented as 
the absolute difference in proportions, the adjusted odds ratio (OR), with 95% confidence 
interval (CI) and p-value. A number of potential effect modifiers and confounders (age, 
history of atopy, season randomised, recent use of antibiotics for ear infection, number of 
previous episodes, duration of symptoms, household smoking, deprivation score, and 
previous tonsillectomy or adenoidectomy) were entered into the primary regression analysis, 
with interaction terms, in order to conduct pre-specified subgroup analyses. Secondary 
outcomes with a binary outcome (present/absent) measured over multiple follow-up time 
points such as satisfactory hearing and presence of effusion, were analysed using repeated 
measures logistic regression. For continuous secondary outcomes such as PedsQL, HUI3 and 
OM8-30 scores, repeated measures linear regression models (using transformations as 
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necessary) investigated differences between the treatment groups  and over time (5 weeks, 6 
and 12 months), adjusting for baseline. Child symptoms were combined and examined 
weekly over time. A Cox regression model was used to test differences in time to insertion of 
ventilation tubes. The cost effectiveness analysis was from the perspective of the UK NHS 
and Personal Social Services. Costs of the course of oral steroids was calculated and 
combined with differences in costs between intervention and control groups to determine 
overall costs associated with the intervention. The resource utilisation of both groups 
(consultations, medications, operations, equipment, etc.) and treatments associated with 
adverse events, were assessed through the completion of self-completed questionnaires at 
baseline, at 5 weeks, 6 months and 12 months and translated into costs using appropriate 
published unit costs. The difference in overall costs between groups was compared with 
differences in outcomes, including Quality-adjusted Life Years (QALYs) computed from the 
HUI3 and from utilities derived from mapping responses to the OM8-30 questionnaire. A 
series of one-way sensitivity analyses were conducted to assess the impact of parameter 
variation on baseline estimates of the cost effectiveness ratios and a probabilistic sensitivity 
analysis undertaken to determine the extent to which the intervention can be regarded as 
representing value for money. 
 
Results 
Participants were recruited from 20 sites between March 2014 and April 2016. A total of 
1,018 children were assessed for eligibility, with 389 children (38%) randomised. The main 
reasons for exclusions were failure to meet the hearing loss criteria (n=264), failure to meet 
other inclusion criteria (n=239), and parental decision to not participate (n=124). The 
baseline demographics of the randomised children were well balanced. Slightly more boys 
were randomised, and the majority identified as white. Around 30% were on the waiting list 
for ventilation tube insertion. Method of audiometry was balanced across trial groups. Over 
85% of ears were tested over four frequencies (0.5, 1, 2 and 4) using ear specific methods, 
with around 80% tested over four frequencies using the soundfield. Hearing loss was slightly 
worse in the oral steroid group, and most children had mild to moderate hearing loss. Over 
95% of ears had type B (flat) tympanograms. 316 (81%) children attended all three 
assessments, 14 attended the 5-week assessment only, four attended only 6 and 12 months, 38 
attended two of the three, and four children missed their 5-week assessment but returned for 
the 6 and 12 month assessment. Over 90% of participant diaries were returned; 98% reported 
initiating treatment and 88% reported taking all or some medication for all 7 days, with most 
reporting taking the medication fully as prescribed. 
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17 children did not have their hearing assessed at 5 weeks either due to loss to follow-up, or 
because the audiologist was unable to carry out the assessment. In the ITT population of 363 
children, 132 demonstrated acceptable hearing at 5 weeks: 59 (33%) of 180 children in the 
placebo group and 73 (40%) of 183 in the oral steroid group. The between group difference 
of 7.1% (95% CI: -2.8 to 16.8%) results in a number needed to treat (NNT) = 14.1 (95% CI: 
numbers needed to treat to harm (NNTH) 35.7 to ¥ to numbers needed to treat to benefit 
(NNTB) 6.0). At 5 weeks follow up, the odds of having acceptable hearing were 32% higher 
for children randomised to oral steroid (OR 1.36, 95% CI 0.88 to 2.11; p=0.164) compared to 
children randomised to placebo. Sensitivity analyses using a per protocol population (PP) 
showed no significant difference between groups. The complier average causal effect 
(CACE) analysis found an increase to 8.0% in the difference between groups after adjusting 
for full adherence. For all subgroups, no differences in treatment effects were found and the 
p-values for the interaction term (treatment group by subgroup) in the model ranged from 
0.04 to 0.74. 
 
There was a considerable increase in acceptable hearing at 6 and 12 months compared with 5 
weeks, with a constant 7 to 8% difference between treatment groups at each time point. There 
was no overall difference in acceptable hearing between and no differential effect of 
treatment over time. There was no significant difference in the proportion with 
tympanometric evidence of resolution of OME at each time point, however as a time-
dependent variable, improvement over time was significantly greater in the oral steroid group 
(p=0.007). Between 5 weeks and 6 months follow-up, around 22% of both groups had 
ventilation tubes inserted, and between 6 and 12 months 14% and 13% of children in placebo 
and oral steroids groups had ventilation tubes inserted. There was no evidence of a difference 
between treatment groups at each follow-up time point, but there was a differential treatment 
effect over time (p=0.017). Functional health status and quality of life (QoL) improved over 
time in both groups, but there were no statistical or meaningful differences between treatment 
groups. There were no significant differences in number of healthcare consultations, time off 
school, nursery or work. Weekly symptom scores were generally low with a skewed 
distribution. Scores in both groups reduced over time with no difference. Only one participant 
(in placebo group) had a serious adverse event (asthma exacerbation requiring 
hospitalisation). Potential adverse events were reported by 22 (12.9%) and 25 (14.0%) 
children during week 1 in the placebo and oral steroid group respectively, with no apparent 
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difference between groups. Gastrointestinal symptoms were reported by 11 (4.7%) and 7 
(3.9%), and behavioural changes were reported in 3 (1.8%) and 7 (3.9%) children in the 
placebo and oral steroid groups respectively. 
 
The primary cost effectiveness analysis demonstrated an incremental cost of achieving an 
additional hearing resolution at 5 weeks as a result of oral steroid treatment of £690, and 
increasing to £3,052 at 12 months. The primary cost utility analysis (incremental cost per 
QALY gain at 12 months) found evidence for oral steroids being dominated by placebo (i.e. 
less effective and more costly)  However, the differences in costs and outcomes were small 
and not statistically significant, with sensitivity analyses suggesting considerable uncertainty, 
and the results need to be interpreted in the context of the clinical effectiveness findings.  
.  
Conclusions 
If effective, a short course of oral steroids for OME would have been very appealing as it is 
generally well tolerated, and would avoid more burdensome and expensive interventions such 
as ventilation tube surgery or hearing aids. Although we found an absolute increase of 7.1% 
in the proportion of children with acceptable hearing at 5 weeks after randomisation treated 
with steroid, that was maintained at 6 and 12 months, these differences were not statistically 
significantly different. We did not identify any subgroup that received meaningful advantage 
from steroid treatment. In addition, we did not find any differences in functional health status 
and QoL measures between treatment groups. Therefore, even if the small benefit seen in 
terms of hearing resolution is not a chance finding, it is unlikely to be clinically significant. 
 
This trial has produced unique data about the generally favourable natural history of 
problems associated with persistent OME with proven bilateral hearing loss. This data can 
help inform a shared decision making approach to the management of OME, including the 
‘watchful waiting’ option. Studies exploring the optimal ways of sharing natural history and 
intervention effect data with parents, as well as further evaluations of alternative pathways, 
will help improve the management of this common and important problem.  
 
The OSTRICH findings suggest that any benefit from a short course of oral steroids for OME 
is likely to be small and of questionable clinical significance, and unlikely to be cost-
effective, and therefore we cannot recommend routine use.  
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Chapter 1 Introduction 
Importance of the problem 
Otitis media with effusion (OME) is the commonest cause of hearing loss in children in the 
UK, and up to 80% of children are affected by OME by 4 years of age.2 Overall, the 
prognosis for OME is good, with over 50% of OME episodes resolving spontaneously within 
3 months and 95% within 1 year. However, 30-40% of children have recurrent OME 
episodes, and 5% of preschool children (aged less than 5 years) have persistent (longer than 3 
months) bilateral hearing loss associated with OME.3 
 
Hearing loss from OME can have an important impact on children’s mood, communication, 
concentration, learning, socialisation and language development. This may affect other 
family members and family function. OME in early childhood can affect intelligence quotient 
(IQ), behaviour, and reading into teenage years.4 
 
The UK National Institute of Clinical Excellence (NICE) guideline (2008) for OME 
management recommends a ‘watchful waiting’ period of 3 months, with referral to an Ear, 
Nose and Throat (ENT) department if hearing is significantly affected, OME persists for 
longer than 3 months, or if there is suspected language or developmental delay.5 Similar 
recommendations come from the American Academy of Pediatrics and the American 
Academy of Otolaryngology.6, 7 Treatment options for these children are limited to hearing 
aids or surgical insertion of ventilation tubes (grommets or tympanostomy tubes) through the 
tympanic membrane. Hearing aids are an effective treatment, but this intervention is not 
problem-free; children often find them uncomfortable, may feel self-conscious, and become a 
target for bullying.8  
 
Although the diagnosis of OME in primary care has increased over the last decade, the 
number of grommet operations performed in England fell from 43,300 in 1994-1995 to 
25,442 in 2009-2010, primarily as a result of the ‘watchful waiting’ strategy.9  However, 
OME remains the commonest reason for childhood surgery in the UK and comprises a 
considerable workload for hospital ENT departments. Furthermore, there is wide variation in 
the rate of grommet surgery between regions that is unlikely to be explained by variation in 
disease. In Wales, there is six-fold variation in the European age-standardised rates of 
grommet surgery between the highest and the lowest local authorities.10 
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Both hearing aids and surgery require referral to secondary care with risks and major cost 
consequences: The Department of Health commissioned ‘McKinsey’ report states that the 
National Health Service (NHS) could save £21 million per year by reducing grommet 
insertion by a further 90%, a procedure that they assessed as being ‘relatively ineffective’.11 
This position has been challenged. Deafness Research UK and the 2009 ENT UK Position 
Paper conclude that reducing access to grommets will disadvantage thousands of children 
who are in genuine need of treatment.12, 13    
Rationale for current trial 
Antibiotics, topical intranasal steroids, decongestants, antihistamines and mucolytics are all 
ineffective treatments for OME.14-16 A rigorous evaluation of anti-inflammatory treatment for 
OME has been a priority for many years.17 Cochrane systematic reviews have found 
insufficient evidence for the effectiveness of both oral steroids and auto-inflation (AI) devices 
in resolving OME in children to recommend implementation, but sufficient evidence to 
recommend further research.15 
A recent trial of an AI device in children with OME aged 4-11 years has found a modest 
effect for some children.18 However, 80% of children are affected by OME before the age of 
4 years at the time when language development is most rapid and hearing loss has its greatest 
effect on language development.4 Alternative management options to hearing aids or surgery 
for children aged less than 4 years (who are unable to use an AI device) are required.  
Williamson et al. (2009) evaluated topical intranasal steroids for children with OME in 
general practice and found they are unlikely to be clinically effective for OME.19 This may be 
because topical steroids applied through the nose are unlikely to reach the middle ear. 
However, systemic steroids do reach the middle ear epithelium and modulate OME in animal 
models.20  
The evidence from in vitro and animal models suggests that steroids reduce middle ear 
effusions and middle ear pressure.21-24 Various mechanisms have been proposed for a role for 
steroids in resolving middle ear effusions, including: (a) reducing arachidonic acid and 
associated inflammatory mediators, (b) shrinking peri-eustachian tube lymphoid tissue, (c) 
enhancing secretion of eustachian tube surfactant with a resultant improvement in tubal 
function, and (d) reducing middle ear fluid viscosity by its action on mucoproteins.25  
The latest update of the Cochrane review on oral or topical steroids for OME (last search 
August 2010) found no benefit from intranasal steroids.15 However, the review did identify 
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evidence of a statistically significant benefit from oral steroids plus antibiotics versus 
antibiotics alone for OME (five studies, 409 participants, 23% in the intervention group and 
47% in the control group with persistent OME at follow up), and a trend towards a significant 
benefit for oral steroids versus placebo in the short term (3 studies, 108 participants). Oral 
antibiotics alone are not effective. The only study to assess the effect of oral steroids on 
hearing as an outcome was underpowered. 
 
Studies included in the systematic review were short-term, underpowered, often had poorly 
described inclusion criteria and/or did not assess hearing at the time of inclusion, used ears 
rather than children as the unit of analysis, and used intermediate outcome measures, such as 
tympanometry results, rather than improved hearing. No cost effectiveness studies of oral 
steroids for OME were found. Therefore there is insufficient evidence to recommend oral 
steroids as a treatment for persistent OME because of inadequate evidence about short-term 
effect on hearing and cost effectiveness and absence of evidence about longer-term effects.  
Potential harms from oral steroids 
No significant adverse effects from steroids were reported by the studies included in the 
Cochrane review. However, the numbers of participants were too small to rule out that 
possibility. Short courses of Prednisolone are widely used in treating children with acute 
asthma and adverse events are extremely rare; when they do occur, they are largely limited to 
behavioural disturbances and dyspepsia and resolve on withdrawal of the steroid drug. The 
safety of multiple short courses of oral steroid therapy has been evaluated.26 Short courses of 
oral steroids such as Prednisolone do not have lasting negative effects on bone metabolism, 
bone density, adrenal gland function or weight or height, even if used on several occasions 
over the course of a year.27  
Summary 
There is an important evidence gap regarding clinical and cost effectiveness of short courses 
of oral steroid treatment for OME.  Identifying an effective, safe, cost effective, acceptable 
non-surgical intervention for OME in children (including those in the first 4 years of life) for 
use in primary care remains an important research priority.  
The OSTRICH trial aimed to determine the clinical and cost effectiveness of a 7-day course 
of oral Prednisolone (steroid) on improving hearing over the short term in children with 
bilateral OME, as diagnosed at an ENT outpatient or Paediatric Audiology/Audiovestibular 
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Medicine (AVM) clinic, who have had symptoms attributable to OME present for at least 3 
months, and current significant hearing loss (demonstrated by audiometry)1.  
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Chapter 2 Methods 
Summary of trial design 
The OSTRICH trial was a double-blind, individually randomised, placebo-controlled trial 
involving children with persistent OME and significant hearing loss, which aimed to 
determine the clinical and cost effectiveness of a 7-day course of oral steroid on improving 
hearing in children with bilateral OME. The trial was based in secondary care, primarily Ear, 
Nose and Throat (ENT outpatient clinics but also included Paediatric Audiology and 
Audiovestibular Medicine (AVM) clinics. Participating sites were asked to identify children 
(aged between 2 and 8 years) with persistent bilateral OME and significant hearing loss. 
Eligible, consented children were randomly assigned to one of two treatment groups: oral 
steroid or matched oral placebo.  
 
At the baseline visit, participants’ hearing was assessed and parents reported quality of life 
(QoL), impact of OME on the family and health status using established assessment tools. 
Children aged over 5 years were also asked about their QoL.  Parents were asked to complete 
a diary for the first 5 weeks following enrolment to record daily symptom severity, use of 
medication, and healthcare consultations. Participants were followed up at 5 weeks, 6 months 
and 12 months after the day of randomisation. 
 
The main analysis compared hearing resolution at week 5 in the active treatment group (oral 
steroid) and the placebo group.  
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The schedule of events and participant flow for the trial is summarised in Figure 1. 
All parents asked to complete a symptom diary for 5 weeks 
1 week course of oral Prednisolone 
(daily dose of 20mg for 2-5 year 
olds, 30mg for 6-8 year olds) 
 
OSTRICH designated Clinician assesses eligibility criteria, takes full informed 
consent and collects baseline data (including the audiology and tympanometry data 
collected in the screening assessment) 
Randomisation 
1 week course of matched oral 
placebo  
 
Follow-up assessment in ENT/Audiology clinic at 5 weeks 
Outcomes assessed – satisfactory hearing, resolution of OME, functional health 
status, health related quality of life 
 
Primary outcome - satisfactory hearing in one ear (using ear specific methods) 
 or both ears (using soundfield methods) 
 
Children with unsatisfactory hearing at 5 weeks are offered usual clinical 
management options. 
Children (2 - 8 years old) attending ENT outpatient clinics who have a diagnosis of 
OME confirmed in the ENT clinic following audiology and tympanometry 
assessments to confirm hearing loss in both ears. 
Follow-up assessments in ENT/Audiology clinic at 6 and 12 months (outcome 
measures as above) 
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Clinical effectivness objectives 
Primary objective 
The primary objective was to determine the clinical effectiveness of a 7-day course of oral 
steroid on improving hearing at 5 weeks from randomisation in children with bilateral OME, 
who have had symptoms attributable to OME present for at least 3 months, and current 
significant hearing loss (demonstrated by audiometry). Oral steroids are likely to have their 
effect within the first few weeks, and most of the existing evidence is for effect at 4-6 weeks. 
This is, therefore, the time-point at which the maximum effect is expected.  
Secondary objectives 
To assess the longer-term (up to 12 months) effect of the intervention on: 
• hearing, 
• resolution of OME, 
• insertion of ventilation tubes (grommet surgery) rates, 
• symptoms, 
• adverse effects, 
• functional health status, 
• quality of life (QoL), 
 
Setting  
Participants were recruited from ENT outpatient or Paediatric Audiology and AVM clinics 
across Wales and England. 
Site recruitment 
The trial was open to participant recruitment from 19th March 2014 until 31st March 2016. A 
Principal Investigator led each site. 
ENT outpatient clinics and Paediatric Audiology/AVM clinics were considered sites for the 
purpose of the trial. The Clinical Research Network (CRN) in England and the Health and 
Care Research Wales Workforce in Wales supported site recruitment. 
Clinics were invited to take part in the trial by CRN email or newsletter. Interested practices 
were contacted initially by email and asked to provide further information about their 
feasibility for conducting the trial. This was followed up by telephone from the trial team to 
discuss the trial in more detail. 
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Each site involved had a research nurse/coordinator and a local site pharmacy.  
Participant selection 
Children were eligible to join the trial if they attended a participating NHS site for their 
routine care, met the following inclusion criteria and did not meet any of the exclusion 
criteria. 
 
Inclusion criteria 
• Aged 2-8 years (e.g. reached 2nd birthday and not yet reached 9th birthday), 
• Symptoms of hearing loss attributable to OME for at least 3 months (or had 
audiometry proven hearing loss for at least 3 months), 
• Diagnosis of bilateral OME made in an ENT or Paediatric Audiology and AVM clinic 
on the day of recruitment or during the preceding week, 
• Audiometry confirming hearing loss of more than 20 dBHL averaged within the 
frequencies of 0.5, 1, 2 and 4 KHz in both ears by pure tone audiometry (PTA) ear 
specific insert, visual reinforcement audiometry (VRA) or ear specific play 
audiometry, or hearing loss of more than 25 dBHL averaged within the frequencies of 
0.5, 1, 2 and 4 KHz by soundfield VRA or soundfield performance/play audiometry in 
the better hearing ear, on the day of recruitment or within the preceding 14 days, 
• First time in the OSTRICH trial, 
• Parent/legal guardian able to understand and give informed consent. 
Exclusion criteria 
Children with one of more of the following were not eligible for inclusion: 
• Current involvement in another clinical trial of an investigational medicinal product 
(CTIMP) or have participated in a CTIMP during the last 4 months, 
• Current systemic infection or ear infection, 
• Cleft palate, Down’s syndrome, diabetes mellitus, Kartagener’s or Primary Ciliary 
Dyskinesia, renal failure, hypertension or congestive heart failure, 
• Confirmed, major developmental difficulties (e.g. are tube fed, have chromosomal 
abnormalities), 
• Existing known sensory hearing loss, 
• Taken oral steroids in the preceding 4 weeks, 
• Had a live vaccine in the preceding 4 weeks if aged under 3 years, 
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• Has a condition that increases their risk of adverse effects from oral steroids (i.e. on 
treatment likely to modify the immune system or who are immunocompromised, such 
as undergoing cancer treatment), 
• Has been in close contact with someone known or suspected to have Varicella 
(chicken pox) or active Zoster (Shingles) during the 3 weeks prior to recruitment and 
have no prior history of Varicella infection or immunisation, 
• Already has ventilation tubes (grommets), 
• On a waiting list for grommet surgery and anticipate having surgery within 5 weeks 
and are unwilling to delay it. 
Participant recruitment 
Participating clinicians (ENT or Paediatric Audiology/AVM) were asked to identify eligible 
patients with bilateral hearing loss and diagnosis of OME during routine outpatient 
consultations, from current grommet surgery waiting lists or hearing aid review lists. 
Additionally, potentially eligible children were identified in Audiology, AVM, Paediatric 
Audiology and Community Audiology clinics and interested parents/legal guardians were 
directed to the participating OSTRICH clinician.  
 
Informing parents of potentially eligible children about the trial 
Participating sites were asked to identify all children between the ages of 2 and 8 years of age 
who had been referred to the ENT clinic for probable OME and to write to their parent/legal 
guardian(s) (hereafter referred to as parent) to inform them about the trial.  
 
Identification of potentially eligible children 
Participating clinicians identified potentially eligible children who were attending routine 
clinics with bilateral hearing loss or a diagnosis of OME. Parents of children were 
approached about the trial by an ENT/ Audiovestibular clinician (doctor, nurse or 
audiologist). Each child had an audiometry assessment and a clinical assessment (both 
routine procedures for those attending these clinics) before they were assessed for eligibility 
to enter the trial. 
 
The participating clinician assessed eligibility and interested parents of eligible children were 
invited to speak with a designated clinical member of the OSTRICH trial team. This 
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individual explained the trial to the child’s parent and provided them with a written Patient 
Information Sheet (PIS). If the parent had already received the PIS with their clinic invitation, 
then the designated individual went through this with the parent. Age appropriate pictorial 
information sheets were also provided for children who were old enough to use them. 
Informed consent 
Parents were asked to provide informed consent. The clinician taking consent also assessed 
the child’s capacity to understand the nature of the trial, and where appropriate, the views of 
children capable of expressing an opinion were taken into account; children deemed to have 
sufficient understanding were asked to sign an age appropriate assent form. 
Parents were informed that they had the right to withdraw consent from participation in the 
OSTRICH trial at any time, and that the clinical care of their child would not be affected by 
declining to participate or withdrawing from the trial. 
All participating sites were asked to keep an anonymous screening log of all ineligible and 
eligible but not consented/not approached patients. These were used to assess potential 
selection bias. 
Randomisation, blinding and unblinding 
Randomisation 
Randomisation was coordinated centrally by South East Wales Trials Unit (SEWTU), Centre 
for Trials Research (CTR). The randomisation schedule was prepared by the Trial Statistician 
(TS) comprising random permuted blocks that were stratified by site and child’s age. The 
investigational medicinal product (IMP) manufacturer (Piramal Healthcare UK Limited) was 
provided with a list of random allocation numbers linking to either the oral steroid or placebo. 
Whether the allocations relate to the oral steroid or placebo was determined by an 
independent statistician to ensure the TS remained blinded. The allocation numbers were 
used to label the trial medication packs.  Each trial medication pack had a unique 
identification number (Trial Pack number).  
 
As children were recruited, they were assigned the next vacant Participant Identification 
number (PID). Trial medication packs were only released once informed consent had been 
obtained and a consent form signed. Participants were randomised to receive either the oral 
steroid or the matching placebo by receiving the next sequentially numbered Trial Pack 
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allocated to the participant by the site Pharmacy. A designated member of the OSTRICH trial 
site team (where possible) or the participant’s parent/legal guardian collected the pack from 
Pharmacy on behalf of the participant. Participant randomisation was considered to have 
occurred once a consent form was signed and the Trial Pack received. The Trial Pack number 
was then entered onto the participant’s case report form (CRF) by the research nurse. 
Blinding 
The placebo was matched for consistency, colour and solubility, as well as visually in 
identical packaging to the active treatment.  Participants, parents/legal guardians, all clinic 
staff and members of the OSTRICH trial team remained blinded to treatment allocation. 
Unblinding 
The active treatment used in this trial was a licensed product (or placebo) used outside of its 
licensed indication. Parents were provided with information about the medication that their 
child was prescribed which included instructions for use and information on unblinding.  
Withdrawal & loss to follow-up 
Parents were informed that they had the right to withdraw consent for their child’s 
participation in any aspect of the trial at any time. If a parent indicated that they wished to 
withdraw their child from the trial they were asked to give a reason for withdrawal.  
Parents who wished to withdraw their child from the trial were asked to decide whether they 
wished to withdraw their child from: 
• further treatment but participate in all further data collection, 
• active follow-up but allow existing data and their child’s medical records to be used, 
• all aspects of the trial and required all data collected to date to be excluded from 
analysis. 
To minimise loss to follow-up, parents who had given permission to be contacted by short 
message service (SMS) text messaging were sent a reminder of their scheduled appointment 
where possible a few days before the appointment. 
Trial interventions 
Participants were randomised to the active treatment group (oral soluble Prednisolone (oral 
steroid)) or control group (matched oral soluble placebo). Clinicians were blinded to 
allocation and so prescribed the trial intervention (either Prednisolone or placebo); this was 
dispensed by the Site Pharmacy. 
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Oral soluble Prednisolone (oral steroid) 
Participants in the active treatment group received a 7-day course of oral soluble 
Prednisolone. The soluble Prednisolone tablets (5mg) used in this trial were manufactured by 
Waymade PLC trading as Sovereign Medical. The Marketing Authorisation is 
PL06464/0914. 
 
Piramal Healthcare UK Limited who have a Medicines and Healthcare Products Regulatory 
Authority (MHRA) Manufacturing Authorisation (MIA IMP 29595) repackaged and supplied 
the soluble Prednisolone tablets. 
Placebo  
The placebo used in this trial was matched for consistency, colour and solubility as well as 
visually and in its packaging. The placebo was manufactured, packaged and supplied by 
Piramal Healthcare UK Limited.  
Dosage 
Oral steroid or placebo: 
• For children aged 2 to 5 years – single daily dose of 4 tablets (20mg of Prednisolone) 
for 7 days, 
• For children aged over 5 years – single daily dose of 6 tablets (30mg of Prednisolone) 
for 7 days. 
 
The daily dose stated is the most commonly used dose in previous studies of OME, and is 
similar to the standard dose for the treatment of other conditions with inflammatory 
components (such as asthma). 
 
All IMP products were manufactured and reconciled into sealed and labelled ‘Trial Packs’ by 
Piramal Healthcare UK Limited in accordance with Good Manufacturing Practice (GMP) and 
in compliance with the Clinical Trial Regulations.28 Trial materials were stored under the 
conditions specified by the manufacturer (or in the Summary of Product Characteristics 
(SmPCs)) and stored in designated temperature monitored areas at site pharmacies. 
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Trial procedures 
Training 
All staff involved in the trial, including clinicians, research nurses/coordinators and 
pharmacists at sites were provided with written standard operating procedures (SOPs) and 
received trial specific training in trial procedures and good clinical practice (GCP) prior to 
commencing the trial.  
 
Data collection 
The schedule for timing, frequency and method of collection of all trial data is summarised in 
Table 1. Assessments were performed as close as possible to the required time point (e.g. 5 
weeks follow-up at 4 weeks post intervention treatment, +2 week window and 6 and 12 
months follow-up +/- 2 weeks window). 
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Table 1 Summary of data collection 
Data type  Baseline 
Evaluation 
Follow-up Period 
5 weeks 6 months  12 months 
Clinic visit Clinic 
visit/Parent 
diary 
Clinic visit/ 
Questionnaire 
Clinic visit/ 
Questionnaire 
1. Demographics X    
2. Medical History X    
3. Audiometry X X X X 
4. Tympanometry X X X X 
5. Otoscopy X X X X 
6. Medication use  X   
7. Insertion of ventilation 
tubes  
 X X X 
8. Daily symptoms  X   
9. Adverse effects  X   
10. Resource use   X X X 
11. Functional health status 
(OM8-3030) 
X X X X 
12. Health related Quality of 
Life (HUI329, PedsQL31) 
X X X X 
13. SAEs |<- - - - - -as required- - - - - >|   
14. Withdrawals |<- - - - - - - - - - -- - - - - - -as required- - - - - - --- - - - - - - - - -- >| 
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Baseline assessments 
Once informed consent had been obtained the OSTRICH nurse: 
• Registered the participant and their parent to the trial (this included collecting names 
and addresses of the participants and their parents), 
• Completed the medical history and baseline CRFs (which included recording 
audiology, tympanometry and otoscopy assessments), 
• Provided the parent with the trial medication (where possible) or the prescription for 
the parent to take to the pharmacy, and provided the medication guidance and 
instructions for use leaflet of the trial medication, 
• Provided the questionnaire booklet to the parent and completed this with the 
participant (if appropriate), 
• Gave the parent a 5-week symptom diary and provided them with instructions on 
diary completion, 
• Arranged next clinic appointment (at week 5) for the participant to attend with their 
parent (and instructed them to bring any unused medication with them). 
 
Follow-up assessments 
Follow-up assessments for all participants were conducted at week 5 (4 weeks post 
intervention treatment, +2 week window), 6 and 12 months (+/- 2 weeks window).  At the 5- 
week follow-up appointment any unused trial medication was collected and returned to the 
pharmacy for disposal. 
Diary  
Parents were asked to complete a diary for the first 5 weeks. In week 1 this was completed 
daily to record treatment adherence. Thereafter, it was completed weekly for 4 weeks to 
record symptoms, adverse events, healthcare consultations, additional medication taken, time 
off school/nursery and parental time off work. 
Clinical Assessments 
The hearing assessments described in Table 2 were measured at 5 weeks post randomisation 
(4 weeks post treatment), 6 months and 12 months.  
 
 
Table 2 Clinical measurements 
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Measurement Outcome 
Audiometry Hearing in each ear by pure tone audiometry 
(PTA), ear specific insert visual reinforcement 
audiometry (VRA) or ear specific play audiometry) 
or in both ears together by soundfield VRA or 
soundfield performance/play audiometry). 
Tympanometry  
(using calibrated standardised 
tympanometers and modified Jerger 
classification Type B and C 
considered abnormal)32 
Presence of middle ear effusion in each ear. 
Otoscopy Appearance of tympanic membrane. 
 
In current practice, the recommended standard methods to assess hearing thresholds are ear 
specific PTA at 0.5, 1, 2 and 4 kHz in children aged 3 or more, and soundfield VRA in 
children under 3. However, equally those under 3 years of age may comply with PTA. 
Therefore, we recommended that the Audiologist/ Clinician used their judgement on the most 
appropriate method of assessment for the child, and where possible maintain that method for 
the subsequent follow-ups. 
 
We are aware that ear specific VRA through the use of insert earphones is considered ‘gold 
standard’ practice, but believe that soundfield VRA provided a reasonable assessment of the 
child’s level of hearing, and ensured the feasibility of the trial in a range of research sites. 
Although the follow-up of participants was continued for 12 months, after the 5-week 
assessment all participants resumed to ‘usual care’ and all treatment decisions were made by 
their parents in consultation with their Clinician. 
 
Functional health status and quality of life  
Functional health status (via OM8-30)30 and health related quality of life (via PedsQL31 and 
HUI3)29 were assessed at the end of week 5 and at 6 and 12 months, through parent 
completed questionnaires (Appendix 1). Additional questionnaires comprising the child 
version of the PedsQL were given to children aged 5 years and over. There were two age-
specific versions for children aged 5-7 years and 8 years and older. Scoring for the three and 
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nine OM8-30 facets were provided by Professor Mark Haggard.  Further description of how 
these measures were used and interpreted within the economic analysis are described in 
chapter 4 under ‘Outcomes used in the economic analysis’. 
 
Safety monitoring 
Parents were asked to record non-serious adverse reactions or events or possible side effects 
and rate their severity in the parent diary up to the end of the fifth week of participation.  
 
Data management and monitoring 
Data quality 
Data monitoring was conducted throughout the trial across all of the recruiting sites; this 
included a 10% quality control (QC) of all datasets. Further monitoring was triggered if an 
error rate greater than 1% was detected. 
Data cleaning 
The OSTRICH database was built with internal validations and ranges; queries arising during 
data entry were referred back to the site research nurses.  Where data collected on paper 
CRFs conflicted with that collected via the web-based database, the value on the paper CRF 
was deemed the true value unless the paper CRF had already been appropriately annotated 
with a correction.   Self-evident correction (SEC) rules were developed during the course of 
the trial, in response to common errors of CRF completion.   
Research Governance 
This trial had Clinical Trials Authorisation (CTA) from the UK Competent Authority, 
MHRA Reference 21323/0039/001-0001 and was reviewed as risk category Type B. Ethical 
approval was granted from a NHS research ethics committee, recognised by the United 
Kingdom Ethics Committee Authority (UKECA). The initial approval was granted by the 
National Research Ethics Service Research Ethics Committee (REC) for Wales on 
28/02/2013, Reference number 13/WA/0004. NHS Research and Development (R&D) 
approval was sought from the respective NHS relevant organisations in Wales and England.  
The trial was assigned European Union Drug Regulating Authorities Clinical Trials 
(EudraCT) Number (2012-005123-32) and the International Standard Randomised Controlled 
Trial Number (ISRCTN) (49798431) (registered 7 December 2012). 
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Patient and public involvement  
We had a patient and public involvement (PPI) representative who has a child who had 
longstanding OME. She joined the trial as a member of the Trial Management Group (TMG). 
Our Trial Steering Committee (TSC) and Independent Data Monitoring Committee (IDMC) 
also had PPI representatives who had personal experience of children with OME. Our PPI 
representatives made important contributions to reviewing parent and child information 
sheets, providing feedback on the trial protocol and providing guidance on strategies for 
successful recruitment. One of our PPI representatives was also interviewed for a case study 
on BBC Wales News http://www.bbc.co.uk/news/uk-wales-21663787. The trial has also 
benefitted from our PPI representatives contribution during the analysis and dissemination of 
study results and they will continue to contribute to dissemination activities. 
 
Outcome Measures 
Primary outcome measure 
The primary outcome was an assessment of  acceptable hearing at 5 weeks from 
randomisation (4 weeks after conclusion of treatment), where acceptable hearing is defined as 
‘less than or equal to 20 decibel hearing level (dBHL)’ averaged within the frequencies of 
0.5, 1, 2 and 4 kilohertz (kHz) in at least one ear in children assessed by PTA, ear specific 
insert VRA or ear specific play audiometry, and ‘less than or equal to 25 dBHL’ averaged 
within the frequencies of 0.5, 1, 2 and 4 KHz in children assessed by soundfield VRA or 
soundfield performance/play audiometry. These thresholds are based on national guidelines. 
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Secondary outcome measures 
The secondary outcomes assessed the longer–term (up to 12 months) effects of the 
intervention on: 
• Acceptable hearing at 6 and 12 months (defined as above), 
• Tympanometry (using calibrated standardised tympanometers and modified Jerger 
classification Types A, B and C),32  
• Otoscopic findings,  
• Healthcare consultations related to OME and other resource use,  
• Insertion of ventilation tubes (grommet surgery) at 6 and 12 months, 
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• Adverse effects, 
• Symptoms (reported by parent and child if appropriate), 
• Functional health status, 
• Health related quality of life (HRQoL), 
Clinical effectiveness statistical considerations 
Sample size calculation 
The sample size calculation was based on demonstrating a change in the rate of resolution of 
hearing loss at 5 weeks post randomisation (4 weeks post completion of treatment) from 20% 
in the control group to 35% in the intervention group. OME resolves spontaneously in a high 
proportion of children, and some studies have found a significantly higher rate of 
spontaneous resolution. For example, Williamson et al. found a resolution rate in their control 
group of 47%.19 However, we anticipated a lower spontaneous rate of resolution both because 
we only included children who had been symptomatic for at least 3 months, and because we 
were recruiting children in a secondary care setting, where a more severe spectrum of illness 
was anticipated. The Cochrane review of oral steroids for OME reported a ratio of 
proportions for resolution of OME at 2 weeks of 3.80 (95% CI=0.93 to 15.52). In the five 
studies in the Cochrane review of oral steroids vs. placebo, overall there was a 23% recovery 
rate in the placebo plus antibiotic group and a 47% recovery rate in the oral steroid plus 
antibiotic group, a 24% difference (antibiotics on their own are ineffective).15 We selected a 
conservative estimate of 1.75 for our effect size (ratio of proportions) because we believed 
that a 15% absolute increase in the rate of resolution at 5 weeks would represent a clinically 
meaningful benefit that could result in a meaningful reduction in unnecessary operations and 
a related saving in cost for the NHS. In order to demonstrate a difference between 20% and 
35% with an alpha of 0.05 and 80% power we  needed 302 participants (nQuery software 
version 4.0). Our sample size was 380 to allow for a 20% loss to follow-up at 12 months. 
Although our primary outcome data was gathered at 5 weeks, we believed that it was 
important to be able to assess long-term outcomes, and therefore, wanted to ensure that we 
would have sufficient power for longer-term follow-up assessments. 
Statistical Analysis  
A detailed statistical analysis plan (SAP) was developed and signed off by the Chief 
Investigators, TS and approved by the IDMC, before the study trial database was locked and 
any data were examined. Data analysis was conducted in IBM SPSS Statistics (version 
20.0)34 and STATA (version 13.1).35  
20 
 
Definitions of populations 
Screened population: The screened population comprises all children assessed for eligibility 
at initial appointment. 
Intention-to-treat population: The intention-to-treat (ITT) population comprises all 
randomised children and were analysed in the groups they were randomised to (regardless of 
the treatment they received and compliance with the treatment).  
Per-protocol population: The per-protocol (PP) population comprises those randomised who 
satisfied the study eligibility criteria, received and adhered to their allocated intervention for 
the 7 days, and who did not receive any surgery for grommets 5 weeks from randomisation. 
Children who presented more than 14 days before or after the scheduled 5-week visit date 
were considered not to have complied with the trial protocol and were excluded from the PP 
population.  
Analysis 
All of the clinical effectiveness analyses were by ITT without imputation, with outcome 
values compared between groups using mixed-effect two-level regression models to adjust 
for site and age of child (2-5 years, 6-8 years) as stratification variables.   
Primary analyses 
The primary analyses employed a logistic regression model to investigate differences in the 
proportion of children with acceptable hearing at the 5-week post randomisation follow-up 
appointment between the two treatment groups. In addition to age and site, models were 
adjusted for days from randomisation to 5-week follow up. Results are presented as the 
absolute difference in proportions, the adjusted odds ratio (OR) (comparing the odds of an 
event in the oral steroid group compared to placebo), and 95% confidence interval (CI) and p-
value. For comparison to other studies, the relative risk (RR) was also presented. Sensitivity 
analyses were performed using the PP population and using allocation respecting methods 
such as complier averaged causal effects (CACE) modelling to investigate the effect of 
adherence with treatment using instrumental variable regression. This was carried out by 
fitting a structural mean model (White IR. 2005;36 White IR et al. 2011)37.  The definition of 
adherence was taken as taking all 7 days of oral steroid versus partial adherence (<7 days and 
taking some/none over the 7 days).  Imputation was not necessary due to the low numbers of 
children missing primary outcome data.  
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Two effect modifiers were originally identified as a basis for sub-group analyses: age of child 
and history of atopy (presence of eczema, asthma or hay fever). The following further 
identified confounders were defined in advance of any analysis based on best available 
evidence:  
• the season the child was randomised, 
• whether the child received antibiotics for ear infection in last month, 
• number of previous episodes,  
• duration of ear symptoms,  
• number of previous OME episodes (first vs more than one), 
• household smoke present, 
• deprivation score, 
• previous tonsillectomy or adenoidectomy. 
 
Relevant interaction terms were entered into the primary regression analyses for each of the 
outcomes in order to conduct pre-specified subgroup analyses. Since the trial is powered to 
detect overall differences between the groups rather than interactions of this kind, the results 
of these exploratory analyses are presented using confidence intervals as well as p-values.   
One secondary analysis of the primary outcome was proposed using weighted (to account for 
the number of frequencies recorded) average decibel at 5-week follow-up as a continuous 
outcome. As the majority of children had their ears tested at all four frequencies, weighted 
results were very similar to the unweighted so was dropped from the analysis. This outcome 
was modelled two-ways:  
1. as a child level analysis to explore using the average, best or worst hearing levels 
from children assessed via PTA, ear specific insert VRA or ear specific play 
audiometry. 
2. as an ear-level analysis  to account for both ears being tested using the ear specific 
VRA.  
 
Both approaches used multilevel linear regression modelling (1. child nested within site and 
2. ears nested within child nested within site) adjusting for baseline decibel, child’s age at 
recruitment and time of the 5-week follow-up (days). Results were presented as difference in 
adjusted means (oral steroid minus placebo), alongside 95% CI and p-value.  
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Secondary outcomes 
Secondary outcomes with a binary outcome (present/absent) such as satisfactory hearing 
(audiology/tympanometry), otoscopy outcomes (presence of perforation, effusion, bubbles) 
and insertion of ventilation tubes were analysed using repeated measures logistic regression 
to investigate differences between the treatment groups and over time (5-week, 6 and 12 
months follow-up). Time was nested within participants nested within site and included an 
interaction term for time and treatment group to investigate any divergent or convergent 
pattern in outcomes. The global interaction effect was tested. In addition to the 
aforementioned covariates, baseline measures of outcome were also adjusted for where 
possible.  
 
An adjusted multilevel Cox (shared frailty) regression model examined the time (days) since 
recruitment to insertion of ventilation tubes between treatment groups and effect reported as 
an adjusted hazard ratio (HR) alongside 95% CIs. 
 
For continuous secondary outcomes such as HUI3, PedsQL (overall and five domains), and 
OM8-30 scores (total and the three facets), repeated measures linear regression models were 
used to investigate differences between the treatment groups and over time (5 weeks, 6 and 
12 months) adjusting for baseline scores. Transformations (squared and cubed) to the raw 
scores were performed as necessary to improved residuals and model fit. If no 
transformations were suitable, the raw scores were dichotomised and a repeated measures 
logistic regression model used.  The use and interpretation of these measures for the 
economic analysis is described in chapter 4 (health outcome measures). 
 
A number of outcomes were calculated from the parents’ diary for the first 5 weeks such as 
parent–reported symptoms, total days off school/nursery and work for ear and non-ear 
problems, and the number of OME related healthcare consultations. Weekly scores were 
reported on the child’s symptoms on a scale of 0 to 6 (not present to as bad as it could be) for 
eight symptoms (any problems with hearing, ear pain, speech, energy levels, sleep, attention 
span, balance, being generally unwell). The protocol stated that the duration between start 
and resolution of symptom would be examined and modelled using a Cox regression model. 
Given the limited number of weeks of follow-up this analysis was not possible and the 
following analysis proposal was written into the SAP and signed off in advance of sight of 
any data.  
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The correlation between symptom scores in the symptom diary was examined via Cronbach’s 
alpha and factor analysis used to determine whether the eight symptoms could be combined 
in an overall score. This was carried out for symptoms at each week to demonstrate the 
validity of using the total symptom score to measure child illness. For the overall score, a 
multilevel linear repeated measures model (adjusting for age of child and site) was used. 
Changes in nausea and behaviour in mood over time were examined separately. The effect of 
oral steroids are reported as the adjusted difference in means score alongside 95% CIs.  
 
For days off school/nursery and work, and OME related healthcare consultations, these were 
analysed firstly using a Poisson multilevel model, however a Negative Binomial model was 
found to be a better fitting model, according to the Akaike information criterion (AIC). 
Results were presented as the adjusted incident rate ratio (IRR) (in the oral steroid group 
compared to the placebo group) alongside a 95% CI. 
 
Changes to statistical methods from protocol  
The following changes were added to the SAP following publication of the protocol paper 
and approved by the IDMC: 
1. For the primary outcome, in addition to adjusting for child’s age at recruitment, site 
and time to follow-up were also deemed important to adjust for.  
2. A negative binomial model was used instead of the intended Poisson model due to 
over dispersion.  
3. For the symptoms scores, a component was added to combine each individual 
symptom score into an overall score so that the issue of multiple outcomes were 
overcome. 
 
The following changes were omitted from the SAP following publication of the protocol 
paper: 
1. Given the limited number of weeks of follow-up, duration between start and 
resolution of symptom was not examined and modelled using a time to event (Cox 
regression) model. Instead the analysis proposed in point 3 above was included.  
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Additional exploratory analysis 
Additional exploratory analysis were conducted as part of a student research project assessing 
the association between baseline hearing threshold and HRQoL (including both overall 
HRQoL and scores for each domain). Pearson’s correlation coefficient (assuming that the 
distributions were sufficiently normally distributed) was used and 95% Cis and the p-values 
were presented. The Pearson’s correlation coefficient (r) was used to investigate the strength 
of any correlations. 
Decisions about exploratory health economic analyses would be assessed following a review 
of the sub-group analyses described above. 
Summary of changes to the trial 
The main changes to the protocol that occurred during the conduct of the trial are summarised 
below: 
A number of changes were made to the protocol to make it easier for sites to recruit patients 
and schedule the follow-up appointments. For example, we extended our site coverage into 
England, the eligibility criteria for audiometry confirmed hearing loss was extended to 14 
days preceding recruitment, follow-up visits were conducted in ENT or Audiology outpatient 
clinics, the timeframe windows for follow-up were extended to  + 2 weeks for 5-week follow-
up, and +/- 2 weeks for 6 and 12 month follow-ups. Paediatric Audiology and AVM Clinics 
were included as sites, and Audiovestibular Physicians were included as designated 
OSTRICH clinicians. 
 
Additions were made to the exclusion criteria such as ear infections, Kartagener’s or Primary 
Ciliary Dyskinesia, existing known sensory hearing loss, undergoing cancer treatment, on a 
waiting list for grommet surgery and anticipated having surgery within 5 weeks and 
unwilling to delay it, live vaccines 4 weeks prior to recruitment if aged under 3 years old. 
 
A number of changes to the planned trial procedures were made due to time constraints 
resulting from the longer than anticipated recruitment period. For example, removal of 
medical notes search and data linkage used to identify healthcare consultations during the 12 
month follow-up period in secondary care and primary care. As a result of this, a specific 
assessment of resource use at baseline could not be collected.  
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Lastly, a number of further amendments were made to the protocol such as sending reminders 
for follow-up appointments and contacting parents regarding missed appointments and 
exploratory analysis to assess association between baseline hearing threshold and quality of 
life. We also undertook a qualitative sub-study to explore parents’ understanding of the 
treatment options available to them, their views on shared decision making in the context of 
managing glue ear and their views on the use of oral steroids for glue ear. Further changes 
were made to the proposed longer –term modelling to be conducted as part of  health 
economic analysis as a result of the trial results which are explained in detail in Appendix 2. 
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Chapter 3 Results 
Site recruitment 
We initially planned to recruit participants from seven secondary care sites in Wales; 
however, it became apparent that it would not be possible to recruit all 380 children in the 
allotted time from Wales only; recruitment was therefore extended to sites in England. In 
total 35 expressions of interest (EOIs) were received; 13 from enquiries made by 
Comprehensive Local Research Network (CLRN) research leads and a further 15 as a result 
of a call from the Medicines for Children Clinical Research Network (CRN) and NIHR ENT 
Speciality Group. Ten sites did not progress any further as they felt unable to commit to the 
recruitment target or were no longer looking to take on new studies. The process of obtaining 
local R&D approval was started for two sites but was not progressed due to the lengthy time 
taken for initial discussions and approvals. A breakdown of the number of sites who 
expressed an interest in participating, agreed to participate and actively recruited is presented 
in Figure 2. 
 
 
Figure 1 Site recruitment flow 
 
 
23 sites initiated into OSTRICH 
(92% of sites that agreed to participate) 
 EOIs were received from 35 secondary care 
sites  
Wales = 7, England = 28 
10 (29%) were not recruited 
after EOI received  
25 sites agreed to participate in OSTRICH 
(71% of EOIs) 
 2 (8% of sites that agreed to 
participate) were withdrawn 
before initiation 
3 (13% of sites initiated) did 
not actively recruit (and were 
closed early) 
20 (87% of initiated sites) actively recruited 
at least one participant into OSTRICH 
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Participant recruitment and trial flow profile 
The first child was randomised on 20th March 2014 and the last on 5th April 2016. The flow 
of children through the trial is represented in the Consolidated Standards of Reporting Trials 
(CONSORT) trial profile diagram in Figure 3.  
 
A total of 1,018 children were assessed for eligibility, with 389 children (38%) randomised 
into the trial over a period of 25 months. A total of 535 reasons for exclusions were given for 
503 children. The main reasons for exclusions were insufficient hearing loss (49.3%) and 
having no diagnosis of otitis media with effusion (OME) on the day of recruitment or the 
preceding week (16.1%). The parents of 126 (12.3%) children declined participation, and a 
small number were unable to be consented at site. The majority (50%) gave no reason for 
declining. The most common reasons given were: ‘having grommets fitted’ (12%), and ‘carer 
not wishing the child to have steroids’ (9%). After randomisation a further six children were 
found to be ineligible and three withdrew from the trial (and declined use of their data), 
leaving 380 children (193 in the oral steroid group and 187 children in the placebo group). 
There was slight differential loss to follow-up for the 5 week clinic appointment (nine vs. 
three in the oral steroid group versus placebo group respectively), but over 95% of the 
population were retained for the analysis of the primary outcome at 5 weeks.  
 
Randomisation was remote and online, and was stratified by site and age of child at 
recruitment (2-5 years and 6-8 years). For the majority of the recruiting sites and children 
aged 2-5 years old, treatment allocation was well balanced (Table 3). There was however, a 
slight imbalance of treatment allocation in the 6-8 years strata and in a few sites. The 
explanation for this imbalance is that there were 53 incomplete blocks of allocations (29 in 
age strata 2-5 years and 24 in age strata 6-8 years). In a site, allocations were stopped mid-
block due to the IMP expiring and requiring disposal or the study recruitment period ending 
mid-block.  
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Figure 2 Main trial CONSORT diagram 
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Table 3 Treatment allocation by site 
Site ID Number  
randomised 
Placebo Oral steroid 
1 76 38 38 
2 28 12 16 
3 7 3 4 
4 41 20 21 
5 7 4 3 
6 13 7 6 
7 3 1 2 
8 64 30 34 
9 26 14 12 
10 30 14 16 
11 18 9 9 
12 3 1 2 
13 22 12 10 
14 6 2 4 
15 5 0 5 
16 1 1 0 
17 13 7 6 
18 14 7 7 
19 8 5 3 
20 4 2 2 
    
Age category    
2-5 year olds 270  134 (49.6) 136 (50.4) 
6-8 year olds 119 55 (46.2) 64 (53.8) 
Total 389 189 (48.6) 200 (51.4) 
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Baseline characteristics  
The baseline demographics of the randomised children were similar in the two groups (Table 
4). Slightly more boys were randomised, and the majority were ethnic white background. 
Over 60% of children were randomised in the Winter or Spring. For over two thirds of 
children, this was their first episode of OME although around 10% in each group had had six 
or more episodes. Over 60% of children had had their current problem for more than 12 
months (Table 4). Comparable numbers of children had previously had a tonsillectomy/ 
adenoidectomy, and a marginally higher proportion in the placebo group had received 
surgery for insertion of ventilation tubes or had been fitted with a hearing aid. Just under 30% 
of children were on the waiting list for ventilation tubes. Of those with a sibling, a quarter 
either currently had or previously had OME. Around 65-70% of children did not have 
asthma, eczema, or hay fever and 15% were on long term medications. Fewer than 10% in 
each treatment group had received antibiotics for an ear infection in the past month.  
 
Ear specific PTA was the favoured hearing assessment in the older age group (6-8 years), and 
is the recommended standard method in children aged 3 or more. The remainder of 6-8 year 
olds had ear specific VRA or play audiometry. Soundfield was only used in 19.3% of 
children aged 2-5 years of age. Method of audiometry was balanced across treatment groups 
(Table 5).  Over 85% of ears using ear specific methods were tested over all four frequencies 
(0.5, 1, 2 and 4) with slightly lower numbers (around 80%) using the soundfield. Hearing loss 
was slightly worse in the oral steroid group with most children having mild to moderate 
hearing loss. Tympanometry and Otoscopy were performed in almost all children, with the 
majority having type B tympanograms, and a small proportion having Type C.  The tympanic 
membrane could be visualised in most ears and appearance suggested presence of middle ear 
infusion. Quality of life was high and comparable between treatment groups (Table 6). 
 
 
 
 
 
 
 
 
 
Table 4 Baseline characteristics of randomised children by treatment group 
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Variables Placebo 
N=187 
Oral steroid  
N=193 
Child demographics   
Age at recruitment  (years) mean (SD)  5.08 (1.60) 5.30 (1.60) 
2-5 years N (%) 133 (71.1) 131 (67.9) 
6-8 years N (%) 54 (28.9) 62 (32.1) 
Gender N (% Male) 102 (54.5) 109 (56.5) 
Townsend deprivation quintile   
1 – least deprived 32 (17.1) 25 (13.0) 
2 16 (8.6) 23 (11.9) 
3 48 (25.7) 45 (23.3) 
4 46 (24.6) 48 (24.9) 
5 – most deprived 45 (24.1) 52 (26.9) 
Ethnicity N (%)   
White  134 (82.7) 143 (82.2) 
Mixed/multiple ethnic 10 (6.2) 10 (5.2) 
Asian/Asian British 13 (8.0) 18 (10.3) 
Black/African/Caribbean/Black British 3 (1.9) 3 (1.7) 
Other ethnic 2 (1.2) 0 (0.0) 
Missing 25 19 
Season randomised N (%)   
Spring (March to May) 64 (34.2) 70 (36.3) 
Summer (June to August) 32 (17.1) 33 (17.1) 
Autumn (September to November) 31 (16.6) 34 (17.6) 
Winter (December to February) 60 (32.1) 56 (29.0) 
Height measured N (%)   62 (33.2) 74 (38.3) 
Height (cm) mean (SD) 112.22 (11.34) 115.08 (10.59) 
Weight measured N (%) 70 (37.4) 75 (38.9) 
Weight (kg) mean (SD) 20.24 (5.49) 21.77 (5.95) 
Body Mass Index (BMI) centile N (%) 60 (32.1) 69 (35.8) 
Median (25th to 75th centiles) 18.5 (16.4 to 23.1) 21.0 (18.7 to 24.6) 
Relation of carer to child N (%)   
Mother 159 (85.5) 171 (88.6) 
Father 24 (12.9) 20 (10.4) 
Other 3 (1.6) 2 (1.0) 
Missing 1 0 
Medical history of children   
First episodes of OME  N (% Yes) 135 (72.2) 128 (66.3) 
Length of time had problems due to this episode of 
OME N (%) 
  
<6 months (m) 26 (13.9) 19 (9.9) 
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Variables Placebo 
N=187 
Oral steroid  
N=193 
6 to <9 m 28 (15.0) 22 (11.5) 
9 to <12 m 18 (9.6) 20 (10.4) 
12 m or more 115 (61.5) 131 (68.2) 
Missing 0 1 
Previous ventilation tubes (grommet surgery) N (% 
Yes) 
19 (10.2) 14 (7.3) 
On waiting list for ventilation tubes N (% Yes) 52 (27.8) 55 (28.6) 
Fitted with hearing aids N (% Yes) 31 (16.6) 27 (14.0) 
if yes, frequency of use:   
Not at all 5 (16.1) 2 (7.4) 
Occasionally 2 (6.5) 2 (7.4) 
Most of the time 8 (25.8) 15 (55.6) 
All of the time 16 (51.6) 8 (29.6) 
Previous tonsillectomy N (% Yes) 8 (4.3) 9 (4.7) 
Previous adenoidectomy  N (% Yes) 8 (4.3) 8 (4.1) 
Family history of OME     
Has a brother or sister? N (% Yes) 147 (78.6) 156 (80.8) 
If yes, at least one currently has or has had 
OME 
34 (23.3) 44 (28.4) 
Missing 1 1 
Atopy N (%)    
None  131 (70.1) 125 (64.8) 
At least one: 56 (29.9) 68 (35.2) 
Asthma 22 (11.9) 21 (11.2) 
Eczema 41 (22.2) 41 (21.6) 
Hay fever 16 (8.7) 21 (11.1) 
Missing 0 3 
Medications   
Presently using medication regularly longer than 
one week  N (% Yes) 
25 (13.4) 32 (16.7) 
Asthma (β-agonist or Corticosteroid inhaler, 
Corticosteroid inhaler in combination) 
20 23 
Leukotriene receptor antagonists 1 2 
Antihistamine 4 2 
Nasal steroids 3 1 
Antibiotics 0 0 
Pain relief (Ibuprofen, Paracetamol) 2 2 
Other 8 17 
Antibiotics for an ear infection in last month  N (% 
Yes) 
13 (7.0) 19 (9.9) 
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Variables Placebo 
N=187 
Oral steroid  
N=193 
Missing 0 1 
Smoking in house (> 5 hours a week) N (% Yes) 56 (29.9) 51 (26.4) 
 
 
Table 5 Baseline clinical hearing assessments by treatment group 
 Placebo 
N=187 
Oral steroid 
N=193 
Audiometry    
Method of audiometry N (%)   
PTA 94 (50.3) 108 (56.0) 
Ear specific VRA 3 (1.6) 2 (1.0) 
Ear specific play audiometry 61 (32.6) 61 (31.6) 
Soundfield VRA 17 (9.1) 16 (8.3) 
Soundfield performance/play audiometry 12 (6.4) 6 (3.1) 
Average decibel (dBHL) that is audible Mean (SD)    
PTA, Ear specific VRA/play audiometry  N=158 N=171 
Right ear  37.07 (7.49) 35.94 (8.59) 
Left ear  37.39 (8.00) 35.89 (8.83) 
Best hearing ear  34.24 (7.21) 32.69 (8.21) 
Worst hearing ear 40.22 (7.10) 39.25 (7.94) 
Average of the two ears  37.23 (6.53) 35.97 (7.51) 
Soundfield  average decibel (dBHL)  
Mean (SD) 
N=29 
41.13 (8.12) 
N=22 
38.35 (9.30) 
Overall (Average of the two ears and soundfield) 37.83 (6.93) 36.25 (7.74) 
Degree of hearing loss (dBHL range) N (%) 
(based on Overall dBHL) 
  
Slight (16-25) 8 (4.3) 13 (6.7) 
Mild  (26-40) 116 (62.0) 134 (69.4) 
Moderate (41-55) 63 (33.7) 44 (22.8) 
Moderate severe (56-70) 0 (0.0) 2 (1.0) 
Severe (71-90) 0 (0.0) 0 (0.0) 
Profound (>90) 0 (0.0) 0 (0.0) 
Tympanometry   
Tympanometry performed N (% Yes) 187 (100.0) 192 (99.5) 
Type: Right ear N (% Yes)   
B (Flat) 181 (96.8) 184 (96.8) 
C (Retracted/negative) 6 (3.2) 6 (3.2) 
Missing 0 3 
Type: Left ear N (% Yes)   
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 Placebo 
N=187 
Oral steroid 
N=193 
B (Flat) 181 (97.8) 182 (95.8) 
C (Retracted/negative) 4 (2.2) 8 (4.2) 
Missing 1 1 
No type B ears 1 (0.5) 3 (1.6) 
One type B ear 8 (4.3) 10 (5.2) 
Two type B ears 177 (95.2) 178 (93.2) 
Otoscopy    
Visualise the Tympanic Membrane: Right ear N 
(%) 
180 (96.3) 192 (99.5) 
If yes:    
Perforation present 0 0 
Appearance suggests presence of middle ear 
effusion 
180 (100.0) 190 (99.0) 
Bubbles behind the ear drum 20 (11.1) 22 (11.6) 
Visualise the Tympanic Membrane: Left ear N (%) 178 (95.2) 189 (97.9) 
If yes:    
Perforation present 2 (1.1) 2 (1.1) 
Appearance suggests presence of middle ear 
effusion 
177 (99.4) 187 (98.9) 
Bubbles behind the ear drum 20 (11.2) 19 (10.1) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 Baseline functional health status and health related quality of life scores 
 Placebo 
N=187 
Oral steroid  
N=193 
HUI-3 Scorea Median (25th to 75th centiles) 0.80 (0.63 to 0.93) 0.79 (0.66 to 0.92) 
Range (Min, Max) -0.16 to 1.00  0.10 to 1.00 
Missing 28 29 
PedsQLb  Median (25th to 75th centiles) 187 189 
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 Placebo 
N=187 
Oral steroid  
N=193 
Physical Functioning  90.6 (78.1 to 100.0) 90.6 (79.7 to 98.4) 
Emotional Functioning  70.0 (60.0 to 85.0) 75.0 (55.0 to 85.0) 
Social Functioning  90.0 (75.0 to 100.0) 90.0 (72.5 to 100.0) 
Psychosocial Health Summary Score 78.8 (63.54 to 87.5) 78.3 (63.4 to 87.1) 
Total Summary Score 82.1 (69.0 to 90.5) 82.6 (68.0 to 90.7) 
Missing 0 4 
School Functioning  75.0 (58.3 to 90.0) 70.0 (58.3 to 85.0) 
Missing 8 10 
OM8-30c Mean (sd) 187 190 
Infection-related physical health factor score -0.31 (1.03) -0.17 (0.99) 
General development impact factor score 0.52 (1.24) 0.48 (1.20) 
Reported hearing difficulties factor score 0.74 (0.78) 0.87 (0.82) 
Total Summary Score 0.47 (1.04) 0.60 (1.03) 
Parent reported overall child’s health N(%)   
Poor 4 (2.2) 6 (3.2) 
Fair  28 (15.1) 29 (15.5) 
Good 61 (33.0) 54 (28.9) 
Very good 56 (30.3) 55 (29.4) 
Excellent 36 (19.5) 43 (23.0) 
Missing 2 6 
a HUI3 (eight attributes) comprises a family of multi-attribute preference-based utility 
measures. High scores indicate better health related quality of life (max =1.00) 
b PedsQL = High scores indicate better quality of life (max=100) 
c OM8-30  = Low/more negative scores indicates better otitis media related quality of life 
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Time of follow-up assessments 
Follow-up assessments were scheduled at 5 weeks (35 days), 6 months (182 days) and 12 
months (365 days) after randomisation. Parents were encouraged to return for assessment as 
close as possible to the scheduled date. Table 7 shows the range of timings for the follow-up 
assessments were comparable between treatment groups. A total of 316 children attended all 
three assessments, 14 attended the 5-week only, 4 attended only 6 and 12 months, 38 attended 
two of the three, and 4 children missed their 5-week assessment but returned for the 6 and 12-
month assessment. The proportion of responders attending clinic within the specified window 
(± 14 days) were high at 5 weeks (~90% in each group) but then decreased over the next two 
time points. A greater proportion of children randomised to oral steroids attended their 
appointments within the window (71% placebo vs. 79% oral steroids at 6 months, and 65% 
vs. 75% at 12 months). 
 
Table 7 Timing of assessments at each follow up clinic appointment (days) 
Treatment 
group Follow-up  n 
n (%) 
Attending 
within 
window  
(±14 days) 
Days between recruitment and clinic assessment 
Mean (SD) 
Median (25th to 
75th centile) Min Max 
Placebo 
5-week  184 165 (89.7) 40.46 (9.14)  37.5 (35 to 42) 28 96 
6 month  172 133 (71.0) 187.72 (21.49) 183 (178.25 to 194) 96 275 
12 month 162 115 (64.8) 371.38 (25.55) 364 (357 to 374.75) 310 512 
Oral 
steroid 
5-week 184 171 (92.9) 39.52 (6.63) 37.0 (35 to 42) 27 71 
6 month 175 139 (79.4) 187.37 (20.73) 183 (179 to 193) 119 276 
12 month 170 127 (74.7) 371.06 (30.93) 366 (358.75 to 373) 294 665 
 
Medication adherence 
A 7-day course of oral steroid or matched placebo was given as a single daily dose of 20mg 
for children aged 2-5 years or 30mg for 6-8 year olds. Over 90% of diaries were returned of 
which over 98% of responders reported to have started medication and hence initiated 
treatment (Table 8). In total, 31 diaries were not returned but all medication had been 
received according to pharmacy records and 79% had reported taking all medication for 7 
days. One participant had not completed the adherence data but had provided dates to enable 
a verification that medication had been taken for the 7 days. Of those initiating treatment, the 
majority initiated treatment the day after recruitment as instructed. More parents reported that 
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the child did not find the oral steroid as palatable (did not like taste or spat out) compared to 
placebo (21 vs. 10). Minimal numbers of children vomited after medication.  
 
Table 8 Parent reported medication adherence 
 Placebo 
N=187 
Oral steroid 
N=193 
Medication received 187 (100.0) 193 (100.0) 
Diary returned N (%) 170 (90.1) 179 (92.7) 
Initiated treatment 167 (98.2) 176 (98.3) 
Implementation N (%)  in those who initiated   
Fully compliant for 7 days (all taken for 7 consecutive 
days) 
134 (80.7) 138 (78.4) 
Partial compliance  32 (19.1) 38 (21.6) 
Compliance unknown  1 (0.6) 0 (0.0) 
All 7 days taken (all/some medication reported) 147 (88.0) 157 (89.2) 
<7 days taken (1-6 days) 19 (11.3) 19 (10.8) 
Persistence   
Medication reported as not stopped  147 (88.0) 157 (89.2) 
Medication stopped at day 5-7 8 (5.4) 10 (5.7) 
Medication stopped at day 1-4 11 (6.6) 9 (5.2) 
Days between recruitment and treatment start n (%)   
0 (same day as recruitment) 4 (2.4) 6 (3.4) 
1 (day after recruitment as instructed) 134 (80.7) 148 (85.1) 
≥2 28 (16.9) 20 (11.5) 
Median (Min, Max) (days)  1 (0 to 20) 1 (0 to 14) 
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Main trial results 
Primary Outcome 
Proportion of children with acceptable hearing between trial groups at 5 weeks post 
randomisation  
The ITT population (children analysed as randomised with primary outcome data) consisted 
of 363 children (placebo=180, oral steroid=183). Of these, 59 (33%) children in the placebo 
group and 73 (40%) children in the oral steroid group had acceptable hearing at 5 weeks, 
resulting in a 7.1% (95% CI: -2.8 to 16.8%) difference between treatment groups and number 
needed to treat to benefit (NNTB) =14.1 (95% CI: NNT to harm (NNTH) 35.7 to ¥ to NNTB 
6.0) Table 9.  
 
The point estimate for treatment effect suggests that the odds of having acceptable hearing at 
5 weeks were 36% higher for children randomised to oral steroid compared with children 
randomised to placebo (Table 9). However, this difference is not statistically significant. 
There was a small effect of clustering of outcome within site (intraclass correlation 
coefficient (ICC) 0.02, (95% CI: 0.003 to 0.20)). The adjusted RR drew a similar conclusion 
of no significant treatment effect at 1.21 (0.92 to 1.60; p=0.169).  
 
Sensitivity analyses showed similar results and no significant difference between treatment 
groups in both the per-protocol population and when adjusting for adherence in a CACE 
analysis. The latter showed a small increase of 1% in acceptable hearing for children whose 
parents stated that they had fully adhered for all 7 days of oral steroid (Table 9). MI was also 
pre-specified in the SAP but as the proportion missing primary outcome in each treatment 
group was minimal (only 17 (5%) of all children), imputation was not carried out and a 
complete case analysis was appropriate.  
 
 
 
 
 
 
 
 
Table 9 Acceptable hearing by treatment group 
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  Placebo 
N=180 
Oral steroid 
N=183 
Adjusteda OR 
(95% CI)  
p-
value 
ITT population   
  Acceptable hearing N(%)     
No 121 (67.2) 110 (60.1) Reference   
Yes  59 (32.8) 73 (39.9) 1.36 (0.88 to 2.11) 0.164 
Per-protocol population  N=116 N=127   
   Acceptable hearing N(%)     
No 76 (65.5) 75 (59.1) Reference  
Yes  40 (34.5) 52 (40.9) 1.27 (0.75 to 2.17) 0.378 
CACE      
Primary analysis   0.07b (-0.02 to 0.16) 0.109 
Full adherence to oral 
steroid (vs. none/some) 
  0.08b (-0.03 to 0.20) 0.103 
a Adjusted for site, child’s age group at recruitment (2-5 years, 6-8 years), and time since 
recruitment to 5-week assessment (days) 
b Adjusted difference in proportions (95% CI)   
 
 
Subgroup analyses 
No differences in treatment effects between subgroups were found (Figure 4) and the p-
values for the interaction term (treatment group by subgroup) in the model ranged from 0.04 
to 0.74 (Appendix 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
Figure 3 Forest plot of subgroup analyses 
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Secondary analysis of primary outcome 
Two secondary analyses of the primary outcome were proposed in the SAP at 5 weeks, using 
the outcome as a continuous measure. This enabled an examination of any improvements or 
deterioration in dBHL over time. This outcome was modelled in two-ways:  
1. as a child level analysis using the average, best or worst hearing levels from children 
assessed via PTA (where two ears were assessed), and the only assessment of hearing 
in those using ear specific insert VRA or ear specific play audiometry. 
2. as an ear-level analysis to account for both ears being tested using the ear specific 
VRA.  
 
For the child level analysis, both treatment group observed a similar decrease over the 5 
weeks of on average, around 7 dBHL, whichever assessment of the both ears was taken 
(average of both, best ear, worse ear) (Table 10). A weighted average decibel at baseline and 
5 weeks was calculated to account for the number of frequencies recorded per ear/child, but 
since most children had their ears tested at all four frequencies, results were very similar 
(Table 10). There was no evidence of a difference between treatment groups with similar 
results (<1 dBHL between group difference). An analysis of each ear was separately 
conducted, and results were similar to the main per-child analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10 Child and ear level analysis of hearing level (dBHL) at 5 weeks by treatment 
group 
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 Treatment 
group  
Baseline 5 weeks Change  
(5 weeks – 
baseline) 
 
  N Mean (SD) 
Weighted 
Mean (SD) 
N Mean (SD) 
Weighted 
Mean (SD) 
Mean (SD) Difference in 
adjusteda 
means (95% 
CI) 
Child level analysis 
Average 
hearing 
level  
Placebo 181 37.79 (6.92) 
37.68 (6.93)  
181 30.99 (11.00) 
30.84 (10.95) 
-6.80 (10.67) -0.56  
(-2.56 to 
1.44) Oral 
steroid 
183 36.25 (7.72) 
36.18 (7.67) 
183 29.32 (10.38) 
29.22 (10.34) 
-6.93 (9.57) 
Best 
hearing 
level  
Placebo 181 35.24 (7.74) 
35.17 (7.74) 
181 28.02 (11.55) 
27.82 (11.46) 
-7.23 (11.59 ) -0.96  
(-3.07 to 
1.16) Oral 
steroid 
183 33.30 (8.46) 
33.24 (8.43) 
183 25.82 (10.80) 
25.71 (10.74) 
-7.48 (10.57) 
Worst 
hearing 
level  
 
Placebo 181 40.33 (7.26) 
40.20 (7.26) 
181 33.96 (11.33) 
33.85 (11.29) 
-6.37 (11.12) -0.37 
(-2.52 to 
1.78) Oral 
steroid 
183 39.19 (8.11) 
39.12 (8.03) 
183 32.82 (11.37) 
32.72 (11.36) 
-6.37 (10.52) 
Ear level analysis 
 Placebo 361 37.81 (7.91) 361 31.01 (11.82) -6.80 (11.79)  -0.78b 
(-2.79 to 
1.23) 
Oral 
steroid 
364 36.20 (8.79) 364 29.38 (11.54) -6.82 (10.98) 
a Adjusted for baseline hearing, site, child’s age group at recruitment (2-5 years, 6-8 years), 
and time since recruitment to 5 week assessment (days) 
b Adjusted for baseline hearing, age at recruitment, time since recruitment to 5-week 
assessment (days), site, and participant. 
 
 
  
43 
 
Secondary outcomes 
Audiometry  
The proportion of children who attended clinic for hearing assessment was over 95% at 5 
weeks, reducing to around 86% by 12 months. Acceptable hearing using audiometry was 
described by examining the proportion of children with acceptable hearing between treatment 
groups at 5 weeks, 6 and 12 months. A total of 306 children had audiology assessments at all 
three time-points, 19 and 26 had no follow-up at 6 months and 12 months only respectively. 
Of the 306 children, 62 had acceptable hearing at each time point (placebo: 25 (13.4%) vs. 
oral steroid: 37 (19.2%)). A repeated measures multilevel logistic regression model (adjusting 
for site and age of child) showed there was a significant increase in acceptable hearing from 5 
weeks to the 6 and 12 months’ time-points, with a constant 7 to 8% difference between 
treatment groups (Table 11(a), Figure 5). There was no overall difference in acceptable 
hearing between groups (oral steroids compared to placebo averaged across all follow-up 
time-points) and no differential effect of treatment over time.  
 
Tympanometric resolution of OME over time 
Of those that attended clinic, tympanometry was performed in over 98% of children at 5 
weeks, a slight decrease at 6 months to 81% and increasing to 90% at 12 months. The main 
reason why tympanometry was not performed was the child had ventilation tubes in situ or 
were about to have surgery for ventilation tubes. Evidence of tympanometric resolution of 
OME is defined as moving from a Type B or C tympanogram at baseline to a type A 
tympanogram in at least one ear at 5 weeks follow-up. Of children that had tympanometry 
performed, a small proportion had evidence of resolution in at least one ear at 5-week, 6 
months and 12 months (Table 11(b)). Whilst there was no overall effect between treatment 
groups or over time, the rate of resolution in the oral steroid and placebo groups had a 
different trajectory (Figure 6).  
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Table 11 Proportion of children with evidence of (a) acceptable hearing at audiology and (b) tympanometric resolution of OME at 5 
weeks, 6 and 12 months by treatment group 
  Placebo  Oral steroid  Time effect  Treatment effecta Treatment x 
Time effect 
  n /N (%) n /N (%) Adjustedb OR 
(95% CI) 
p-value Adjustedb OR 
(95% CI) 
p-value p-value 
(a) Acceptable 
hearing at 
audiometry  
5 weeks 59/180 (32.8) 73/183 (39.9) Reference 
1.42  
(0.91 to 2.21) 
0.121 0.975 6 months 86/166 (51.8) 105/174 (60.3) 2.30 (1.47 to 3.60)  <0.001 
12 months 99/162 (61.1) 118/170 (69.4) 3.46 (2.19 to 5.46) <0.001 
 
(b) Tymp. 
resolution of 
OME 
5 weeks 13/178 (7.3) 7/182 (3.8) Reference 
0.51 
(0.20 to 1.30) 
0.159 0.007 6 months 17/147 (11.6) 26/152 (17.1) 1.69 (0.79 to 3.61) 0.179 
12 months 9/144 (6.3) 31/159 (19.5) 0.85 (0.35 to 2.06) 0.724 
a Treatment effect is oral steroids compared to placebo averaged across all follow-up time points 
b Adjusted for site and child’s age group at recruitment (2-5 years, 6-8 years) 
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Figure 4 Proportion of children with audiometry acceptable hearing over time by 
treatment group 
 
 
Figure 5 Proportion of children with tympanometric resolution (Type A) of hearing 
over time by treatment group 
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Otoscopy 
Otoscopy was performed in over 96% of children over the three follow-up time-points and 
the tympanic membrane was visible for the majority of these children. Very few children had 
a perforation present in at least one ear with no significant difference by treatment group but 
an increase was detected at 6 and 12 months when compared to perforations at 5 weeks 
(Table 12). There was a decrease over time in the proportion of children where the 
appearance of the tympanic membrane suggested presence of a middle ear effusion but no 
difference between treatment groups. There was no evidence of a difference between 
treatment groups in the proportion of children with bubbles present behind the ear drum but 
there was significantly less at 12 months compared to 5 weeks. There was no differential 
effect between treatment group in bubbles present behind the ear drum over time.   
 
Insertion of ventilation tubes (grommet surgery)  
Around a fifth of children had ventilation tubes inserted between 5 weeks and 6 months 
(Table 13). Between 6 and 12 months, less than 15% of children had new operations for 
ventilation tubes. There was no evidence of an overall difference between treatment group 
and a differential treatment effect over time. The mean time to surgery was 165.5 days 
(standard deviation (SD) =104.5) in the placebo group and 168.0 (96.1) days in the oral 
steroid group. When examined in a time to event model, there was no difference in the risk of 
operations for ventilation tubes between treatment groups (aHR=0.98 (0.69 to 1.41)).  
 
Healthcare consultations related to OME and other resource use 
From the 349 diaries that were returned by parents (placebo 179; oral steroid 170), the total 
number of healthcare consultations relating to OME over the 5-week period were examined. 
Very few children consulted with any healthcare setting over the five weeks post 
randomisation (Table 14) with no difference between treatment groups. Similar conclusions 
were made for time taken off school/nursery or days off work for family members, for ear 
problems and other illnesses. 
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Table 12 Otoscopy findings by treatment group over time 
  Placebo  Oral steroid  Time effect  Treatment effecta Treatment x 
Time effect 
  n /N (%) n /N (%) Adjustedb OR (95% 
CI) 
p-value Adjustedb OR 
(95% CI) 
p-value p-value 
Perforation 
present in at 
least one ear 
Baseline  2/184 (1.1) 2/192 (1.0)  
0.78 
(0.37 to 1.66) 
0.520 0.623 
5 weeks 2/169 (1.2) 0/171 (0.0) Reference 
6 months 9/152 (5.9) 6/155 (3.9) 12.43 (2.77 to 55.76) 0.001 
12 months 7/134 (5.2) 6/151(4.0) 9.21 (2.00 to 42.98) 0.004 
Presence of a 
middle ear 
effusion in at 
least one ear 
Baseline  183/184 (99.4) 192/192 (100.0)  
0.70c  
(0.35 to 1.39) 
0.312 0.950 
5 weeks 152/168 (90.5) 150/172 (87.2) Reference  
6 months 96/151 (63.6) 90/154 (58.4) 0.18 (0.10 to 0.33) <0.001 
12 months 80/138 (58.0) 80/151 (53.0) 0.14 (0.08 to 0.26) <0.001 
Bubbles 
present behind 
ear drum in at 
least one ear 
Baseline  23/183 (12.6) 25/190 (13.2)  
1.57  
(0.76 to 3.26) 
0.222 0.165 
5 weeks 15/164 (9.1) 23/169 (13.6) Reference  
6 months 19/147 (12.9) 13/152 (8.6) 1.54 (0.73 to 3.25) 0.260 
12 months 4/135 (3.0) 8/149 (5.4) 0.30 (0.10 to 0.96) 0.042 
a Treatment effect is oral steroids compared to placebo averaged across all follow-up time-points 
b Adjusting for baseline, site and child’s age group at recruitment (2-5 years, 6-8 years)  
c Adjusting for site and child’s age group at recruitment (2-5 years, 6-8 years). Model would not converge with baseline measures.  
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Table 13 Proportion of children planning or having operations for ventilation tubes at 6 
and 12 months by treatment group (over past 6 months) 
 Placebo Oral 
steroid 
Time effect Treatment effecta  Treatment 
x Time 
effect 
 n/N (%) n/N (%) Adjustedb 
OR (95% 
CI) 
p-value Adjustedb 
OR (95% CI) 
p-
value 
p-value 
5 weeks * *      
6 months 38/170 
(22.4) 
39/173 
(22.5) 
Reference  Reference   
12 
months 
23/162 
(14.2) 
23/172 
(13.4) 
0.54 
(0.30 to 0.98) 
0.042 1.10 
(0.64 to 1.89) 
0.728   0.762 
a Treatment effect is oral steroids compared to placebo averaged across all follow-up time- 
points 
b Adjusted for site and child’s age group at recruitment (2-5 years, 6-8 years) 
* Children were not permitted to have ventilation tubes within the first 5 weeks post 
randomisation. 
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Table 14 Healthcare consultations relating to OME and other resource use 
 Placebo 
N=170 
Oral steroid  
N=179 
Adjusteda IRRb 
(95% CI) 
p-value 
Healthcare consultations relating to OME 
No consultations N (%) 146 (85.9) 162 (90.5) Reference   
At least one consultation N (%) 24 (14.1) 17 (9.5) 0.64c (0.33 to 1.25) 0.188 
1 consultation 16 (9.4) 13 (7.3)   
2 consultations 5 (2.9) 2 (1.1)   
3 consultations 3 (1.8) 2 (1.1)   
   Adjusteda OR 
(95% CI) 
p-value 
Time off school/nursery/work for ear problems 
No time off taken N (%) 162 (95.3) 173 (96.6) Reference   
Time off taken N (%) 8 (4.7) 6 (3.4) 0.71 (0.14 to 4.08)  0.697 
Min to Max (days) 0.1 to 6.0 0.1 to 7.0   
Time off school/nursery/work for non-ear problems 
No time off taken N (%) 155 (91.2) 171 (95.5) Reference  
Time off taken N (%) 15 (8.8) 8 (4.5) 0.49 (0.14 to 1.66) 0.249 
Min to Max (days) 0.3 to 8.0 1.0 to 7.0    
a Adjusted for site, and child’s age group at recruitment (2-5, 6-8 years) 
b Incidence rate ratio (IRR) of the oral steroid compared to placebo, An IRR< 1 indicating 
more events in placebo and an IRR>1 indicating more events in the oral steroid group.  
c Negative binomial model used due to overdispersion and is a better fitting model 
(determined by Akaike Information Criterion (AIC)). 
 
 
Main clinical diary symptoms  
For the 5 weeks post randomisation, weekly scores were reported by parents on ten 
symptoms on a scale of 0 (problem not present at all) to 6 (problem is as bad as it could be). 
Most symptoms were not present at all (Appendix 4). The following eight problems were 
combined into a single symptom scale to avoid multiple outcomes: hearing, ear pain, speech, 
energy levels, sleep, attention span, balance, and being generally unwell. At 1 week post 
randomisation, Cronbach’s alpha for the eight symptom scores was 0.77 at week 1, indicating 
good reliability between the eight symptoms, suggesting that they could be combined into a 
single symptom score ranging from 0 (problems not present at all) to 48 (all problems are as 
bad as possible). The factor analysis also suggested that these symptoms could form a single 
scale. The Cronbach alpha for the subsequent four weeks were all >0.80, suggesting 
relatively high internal consistency over time. The distributions of the weekly overall 
symptom score was positively skewed indicating no problems (Figure 7). The highest median 
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scores were at the end of week 1 (7 in placebo and 6 in oral steroid) indicating that these 
symptoms were not a problem. When scores were changed into binary outcome (no vs. some 
symptoms), there was no difference between treatment groups not over time (Table 15). Two 
categories of symptoms (nausea, vomiting or indigestion and changes in behaviour and mood 
over time) were examined separately; a high proportion of children had resolution of 
symptoms over time with no difference between treatment groups and over time (Table 15). 
 
 
 
Figure 6 Boxplot of weekly overall symptom score by treatment group 
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Table 15 Summary statistics for weekly overall symptom score, nausea and behaviour change by treatment group 
  Placebo  Oral steroid  Time effect  Treatmenta effect Treatment x Time 
effect 
 Week n /N (%) n /N (%) Adjustedb OR (95% 
CI) 
p-value Adjustedb OR 
(95% CI) 
p-value p-value 
No problem 
with any 
symptomc 
(score of 0) 
1 19 (13.6) 13 (8.7) Reference 
0.59  
(0.28 to 1.27) 
0.178 0.801 
2 20 (13.4) 18 (11.6) 1.00 (0.50 to 1.99) 0.990 
3 22 (14.7) 19 (12.3) 1.09 (0.55 to 2.15) 0.807 
4 17 (11.4) 21 (13.2) 0.83 (0.40 to 1.69) 0.600 
5 21 (14.7) 22 (13.8) 1.10 (0.55 to 2.19) 0.789 
No symptoms 
of nausea, 
vomiting or 
indigestion 
1 132 (79.5) 124 (72.5) Reference 
0.67  
(0.40 to 1.11) 
0.116 0.806 
2 136 (83.4) 138 (81.2) 1.30 (0.74 to 2.28) 0.355 
3 145 (87.3) 142 (83.5) 1.78 (0.98 to 3.23) 0.057 
4 138 (84.1) 144 (84.7) 1.37 (0.78 to 2.41) 0.278 
5 136 (85.0) 143 (84.6) 1.46 (0.82 to 2.59) 0.201 
No symptoms 
of changes in 
behaviour and 
mood 
1 96 (58.2) 90 (52.9) Reference 
0.76  
(0.49 to 1.19) 
0.231 0.779 
2 97 (59.9) 105 (61.4) 1.09 (0.69 to 1.70) 0.723 
3 102 (62.6) 113 (66.9) 1.20 (0.76 to 1.89) 0.425 
4 105 (65.2) 111 (66.1) 1.35 (0.85 to 2.13) 0.201 
5 106 (67.1) 113 (67.7) 1.47 (0.92 to 2.34) 0.104 
a Treatment effect is oral steroids compared to placebo averaged across all follow-up time-points 
b Adjusting for site and child’s age group at recruitment (2-5 years, 6-8 years) 
c Hearing, ear pain, speech, energy levels, sleep, attention span, balance and being generally unwell  
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Additional symptoms  
Additional parent reported symptoms from the free text box in the diary were examined. The 
number of children reporting any other symptoms were balanced over time (Table 16). A list 
of the symptoms for week 1 are listed in Appendix 5.   
 
Table 16 Parent reporting other symptoms by week post recruitment by treatment 
group 
 Placebo 
N=170 
Oral 
steroids 
N=179 
Week 1 (administration of medication) 22 (11.8) 25 (14.0) 
Week 2 (1 week post medication) 15 (8.8) 15 (8.4) 
Week 3 (2 weeks post medication) 16 (9.4) 16 (8.9) 
Week 4 (3 weeks post medication) 15 (8.8) 17 (9.5) 
Week 5 (4 weeks post medication) 12 (7.1) 14 (7.8) 
 
 
Adverse events 
Only one adverse event (AE)/ Serious Adverse event (SAE) was reported during the trial in 
the placebo group, where the child had an asthma attack. No between treatment group 
comparison was made. 
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Functional health status: OM8-30  
The otitis media (OM8-30) questionnaire assesses the child’s functional health status as 
overall score and three facets: infection related physical health, general developmental 
impact, and reported hearing difficulties. A low (more negative) score indicates a better 
quality of life. Table 17 shows that the total OM8-30 score decreases over time. This 
decrease on score was also reflected in the three facets but there were no discernible 
difference in trends over time by treatment group.  
 
 
Health related quality of life: PedsQL and HUI3 
Table 18 displays the summary statistics for baseline and follow-up (5 weeks, 6 and 12 
months) for the total PedsQL scores and by each of the five domains. Higher scores indicate 
better QoL. For all domains, the QoL was high and increased over time with a negatively 
skewed distribution, with a high proportion of parents reporting higher QoL for their 
children. For all PedsQL outcomes, there were no differences between groups nor significant 
trends over time.  
 
 
The HUI3 comprises a family of multi-attribute preference-based utility measures where 
scores can range from -0.36 to 1.00 where higher scores indicate better HRQoL. At all 
follow-up time-points the HUI3 distribution was negatively skewed, with a high proportion 
of parents reporting higher quality of life for their children (Figure 8). The decision was taken 
to recode the score as a binary variable based on the maximum score of 1 (healthy) versus 
scores <1 (Table 19). There was an increase in the proportion over time, no evidence of a 
difference between treatment groups and no discernible difference between treatment groups 
over time.   
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N 159 164 155 164 152 155 142 150 
Median 
(25th to 
75th 
centile) 
0.80  
(0.63 to 
0.93) 
0.79  
(0.66 to 
0.92) 
0.85  
(0.66 to 
0.95) 
0.84  
(0.64 to 
0.97) 
0.92  
(0.75 to 
1.00) 
0.88  
(0.73 to 
1.00) 
0.92  
(0.77 to 
1.00) 
0.92  
(0.73 to 
1.00) 
Figure 7 Boxplot of HUI3 score by time and treatment group 
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Table 17 Mean (sd) OM8-30 scorea and by each facet by treatment group 
  Placebo  Oral steroid  Time effect Treatment effectb Treatment x 
Time effect 
  N Mean (SD) N Mean (SD) Adjustedc mean 
difference (95% 
CI) 
p-value Adjustedc mean 
difference 
(95% CI) 
p-
value 
p-value 
To
ta
l 
O
M
8 -
30
 
sc
or
e 
Baseline  187 0.47 (1.04) 190 0.60 (1.03)  
0.05 (-0.12 to 
0.22)  0.539 0.301 
5 weeks 177 0.33 (1.08) 182 0.49 (1.11) Reference 
6 months 158 -0.13 (1.13) 163 -0.14 (1.19) -0.44 (-0.62 to -0.27) <0.001 
12 months 150 -0.29 (1.20) 154 -0.22 (1.18) -0.56 (-0.74 to -0.38) <0.001 
In
fe
ct
io
n 
re
la
te
d 
ph
ys
ic
al
 
he
al
th
 
fa
ce
t 
Baseline  187 -0.31 (1.03) 190 -0.17 (0.99)  
0.04 (-0.12 to 
0.20) 0.666 0.591 
5 weeks 177 -0.44 (0.98) 182 -0.30 (1.00) Reference  
6 months 158 -0.67 (0.90) 163 -0.68 (0.95) -0.25 (-0.42 to -0.09) 0.003 
12 months 150 -0.69 (0.90) 154 -0.57 (1.04) -0.25 (-0.41 to -0.08) 0.004 
G
en
er
al
 
de
ve
lo
p -
m
en
t 
im
pa
ct
 
fa
ce
t  
Baseline  187 0.52 (1.24) 190 0.48 (1.20)  
0.08 (-0.07 to 
0.23) 0.314 0.292 
5 weeks 177 0.54 (1.24) 182 0.58 (1.18) Reference  
6 months 158 0.44 (1.19) 163 0.43 (1.18) -0.04 (-0.20 to 0.12) 0.630 
12 months 150 0.29 (1.19) 154 0.25 (1.16) -0.18 (-0.34 to -0.02) 0.024 
R
ep
or
te
d 
he
ar
in
g 
di
ffi
cu
lti
es
 
fa
ce
t 
Baseline  187 0.74 (0.78) 190 0.87 (0.82)  
0.03 (-0.13 to 
0.20) 0.692 0.866 
5 weeks 177 0.58 (0.88) 182 0.67 (0.87) Reference  
6 months 158 0.04 (0.88) 163 0.06 (0.99) -0.54 (-0.72 to -0.37) <0.001 
12 months 150 -0.05 (0.91) 154 -0.04 (0.99) -0.63 (-0.81 to -0.45) <0.001 
a OM8-30  = Low/more negative scores indicates better otitis media related quality of life 
b Treatment effect is oral steroids compared to placebo averaged across all follow-up time-points 
c Adjusting for site, child’s age group at recruitment (2-5 years, 6-8 years), and baseline OM8-30 score 
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Table 18 Median (25th to 75th centiles) total PedsQL scorea and each domain by treatment group 
 
 
 Placebo  Oral steroid  Time effect  Treatment effectb Treatme
nt x 
Time 
effect 
 
 N Median (25th to 
75th centile) 
N Median (25th to 
75th centile) 
Adjustedc estimate 
(95% CI) 
p-value Adjustedc 
estimate 
(95% CI) 
p-value p-value 
To
ta
l 
Pe
ds
Q
L  
Baseline  187 82.1  
(69.0 to 90.5) 
189 84.8  
(73.8 to 92.7) 
 
-85.11d  
(-420.65 to 
250.44) 
0.619 0.475 5 weeks 176 84.8  
(73.8 to 92.7) 
182 84.5 
(72.4 to 91.7) 
Reference  
6 months 158 84.5  162 82.6  -32.11d 0.856 
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 Placebo  Oral steroid  Time effect  Treatment effectb Treatme
nt x 
Time 
effect 
 
 N Median (25th to 
75th centile) 
N Median (25th to 
75th centile) 
Adjustedc estimate 
(95% CI) 
p-value Adjustedc 
estimate 
(95% CI) 
p-value p-value 
(75 to 90.7) (72.6 to 94.6) (-378.89 to 314.67) 
12 months 149 85.7  
(77.7 to 92.9) 
154 86.9  
(75.0 to 95.2) 
146.53d 
(-205.89 to 498.94) 
0.415 
Ph
ys
ic
al
 h
ea
lth
 
Baseline  187 90.6  
(78.1 to 100.0) 
189 90.6  
(79.7 to 98.4) 
 
0.84e (0.51 
to 1.37) 0.480 0.554 
5 weeks 176 90.6 
(81.3 to 100.0) 
182 90.6 
(80.5 to 100.0) 
Reference  
6 months 158 93.8 
(81.3 to 100.0) 
162 93.8  
(77.3 to 100.0) 
0.90e (0.54 to 1.49) 0.675 
12 months 149 93.8  
(85.0 to 100.0) 
154 93.8  
(84.4 to 100.0) 
 
 
 
1.39e (0.85 to 2.28) 0.195 
Em
ot
io
na
l 
fu
nc
tio
ni
ng
 
Baseline  187 70.0  
(60.0 to 85.0) 
189 75.0  
(55.0 to 85.0) 
 
2.02f (-1.85 
to 5.89) 0.306 0.778 
5 weeks 175 75.0  
(60.0 to 90.0) 
182 75.0  
(60.0 to 90.0) 
Reference  
6 months 158 70.0  
(55.0 to 85.0) 
162 75.0  
(60.0 to 95.0) 
1.17f  (-4.46 to 
6.79) 
0.684 
12 months 149 75.0  
(60.0 to 90.0) 
154 80.0 
(65.0 to 100.0) 
2.05f  (-3.67 to 
7.77) 
0.482 
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 Placebo  Oral steroid  Time effect  Treatment effectb Treatme
nt x 
Time 
effect 
 
 N Median (25th to 
75th centile) 
N Median (25th to 
75th centile) 
Adjustedc estimate 
(95% CI) 
p-value Adjustedc 
estimate 
(95% CI) 
p-value p-value 
So
ci
al
 F
un
ct
io
ni
ng
 Baseline  187 90.0  
(75 to 100) 
189 90.0  
(72.5 to 100.0) 
 
1.20e (0.75 
to 1.92) 0.436 0.854 
5 weeks 175 90.0 
 (80.0 to 100.0) 
182 90.0  
(73.8 to 100.0) 
Reference  
6 months 158 90.0  
(80.0 to 100.0) 
162 90.0  
(70.0 to 100) 
0.81e (0.50 to 1.32) 0.403 
12 months 148 95.0  
(80.0 to 100.0) 
154 95.0  
(78.8 to 100.0) 
1.10e (0.67 to 1.79) 0.717 
Sc
ho
ol
 F
un
ct
io
ni
ng
 
Baseline  179 75.0  
(58.3 to 90.0) 
183 70.0  
(58.3 to 85.0) 
 
-240.53d   
(-718.72 to 
237.65) 
0.324 0.916 
5 weeks 172 80.0  
(65.0 to 91.7) 
176 77.5 
(60.0 to 90.0) 
Reference  
6 months 154 83.3 
(66.3 to 95.0) 
156 80.0  
(66.67 to 90.0) 
184.37d 
 (-308.02 to 
676.76) 
0.463 
12 months 143 83.3 
(66.67 to 91.7) 
147 80.0  
(60.0 to 95.0) 
217.95d  
(-286.59 to 722.49) 
0.397 
Ps
yc
ho
so
ci
al
 Baseline  187 78.8  
(63.5 to 87.5) 
189 78.3  
(63.4 to 87.1) 
    
5 weeks 175 81.7  
(69.2 to 90.0) 
182 81.2  
(67.3 to 90.0) 
Reference  
0.71e (0.26 
to 2.00) 0.509 0.577 
6 months 158 80.0  162 79.0  1.57e (0.64 to 3.90) 0.327 
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 Placebo  Oral steroid  Time effect  Treatment effectb Treatme
nt x 
Time 
effect 
 
 N Median (25th to 
75th centile) 
N Median (25th to 
75th centile) 
Adjustedc estimate 
(95% CI) 
p-value Adjustedc 
estimate 
(95% CI) 
p-value p-value 
(70.0 to 90.0) (67.5 to 93.3) 
12 months 149 82.7  
(71.4 to 91.7) 
154 84.0  
(69.8 to 93.6) 
1.45e (0.57 to 3.66) 0.433 
a PedsQL = High scores indicate better quality of life (max=100) 
b Treatment effect is oral steroids compared to placebo averaged across all follow-up time-points 
c Adjusted for site, child’s age group at recruitment (2-5, 6-8 years), and baseline PedsQL score 
d Squared transformation used on the raw scores. Parameter estimate =adjusted difference in squared means;  
e Outcome transformed to binary: perfect health (score=100) vs non-perfect health ( <100) . Parameter estimate =adjusted odds ratio; 
f  No transformation used. Parameter estimate displayed as adjusted difference in mean 
 
Table 19  Summary statistics for the HUI3 scorea by treatment group 
  Placebo  Oral steroid  Time effect  Treatment effectb Treatment x 
Time effect 
  N (%) N (%) Adjustedc OR 
(95% CI) 
p-value Adjustedc OR 
(95% CI) 
p-value p-value 
N (%) 
perfect 
health 
score=1 
Baseline  22 (13.8) 22 (13.4)  
1.23  
(0.66 to 2.27) 0.511 0.790 
5 weeks 33 (21.3) 37 (22.6) Reference  
6 months 49 (32.2) 52 (33.5) 2.36 (1.31 to 4.26) 0.004 
12 months 44 (31.0) 51 (34.0) 1.99 (1.09 to 3.65) 0.025 
a High scores indicate better health related quality of life (max =1.00) 
b Treatment effect is oral steroids compared to placebo averaged across all follow-up time points 
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c Adjusted for site, child’s age group at recruitment (2-5, 6-8 years), and baseline binary HUI3 score 
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Chapter 4  Economic Evaluation 
This chapter describes the objectives, methods, results and conclusions of the embedded 
health economic evaluation. 
Objectives 
The objectives of the economic evaluation were: 
1. To estimate the costs associated with a 7-day course of oral steroids at 12 months; 
2. To assess the cost effectiveness of a 7-day course of oral steroids to improve hearing over 
the short-term (5 weeks) in children with bilateral OME; 
3. To assess the cost effectiveness of a 7-day course of oral steroids to improve hearing over 
12 months; 
4. To explore the longer-term cost effectiveness of oral steroid treatment.  
The objectives were designed to estimate the likely economic impact of treating OME in the 
target population.  The maximum clinical effect for oral steroid use was expected to occur 
within 4 to 6 weeks. This could result in short-term relief of symptoms and subsequent 
impact on costs as a result of reduced health care resource use. Over the longer-term, these 
could translate into reduced morbidity as a result of OME, impact on HRQoL and possibly 
avoid further treatment e.g. surgical intervention.  The protocol set out an original time 
horizon of 12 months with the plan to undertake a model-based analysis to estimate potential 
longer-term cost effectiveness beyond the trial period. In light of the clinical results presented 
in the preceding chapter, the revision to this objective is explained with modelling plans 
summarised in Appendix 2.   
 
 
Methods 
Resource Usage 
Health and personal social care resource usage was collected for participants at the end of 
week 5 and at 6 and 12 months following randomisation. Parents were asked to report 
healthcare resource use relating to ear problems, and relating to any other illnesses (not 
specified), as separate categories. Healthcare resource use categories included General 
Practitioner (GP) and practice nurse consultations, other community services (e.g. health 
visitor, community audiologist), prescriptions, alongside any other NHS services such as 
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NHS direct. Hospital admissions, out-patient consultations and Accident & Emergency 
(A&E) attendances were also captured, as well as other resource components associated with 
the management of OME and hearing loss e.g. surgical interventions.  Parents had the option 
to tick a range of boxes (0, 1-2 and 3+) and a box to input the exact number if known. Where 
individuals reported a range box without an exact figure, an average (rounded up to next 
whole number) was calculated using the reported resource value from the appropriate range 
group.  All zero (0) options were recorded as above to indicate no resource use; for the other 
options, an average number was recorded.  Where no information was available against a 
resource item, the assumption was made that no resource use had been incurred and it was 
recorded as zero (0). Baseline resource use was not collected. 
 
For medications, parents were asked to provide the name, dosage, duration of treatment and 
whether this was prescribed or not. For non-prescribed medications, parents were asked to 
provide a cost of the medication.  Where information was missing e.g. a medication had been 
listed but dosage and/or duration was not recorded, a cost was estimated based on 
recommended prescribing indications.38 Where a general medication name was given (e.g. 
paracetamol) or abbreviated names given, the lowest price generic medication was used.    
Parents were asked to record any over the counter (OTC) medications used to treat ear-related 
problems (e.g. analgesia). Travel expenses associated with healthcare consultations, costs of 
additional child care and time off work was also recorded. Parents were prompted to provide 
an approximate cost in £ sterling. 
 
The economic  analysis was conducted from the perspective of the UK NHS and Personal 
Social Services and also considered a limited societal perspective, encompassing impact on 
patients and their families. The economic analysis set out to include a within-trial analysis 
and comprised of a series of cost-effectiveness analyses (based on the primary trial outcome 
and secondary outcome;  PEDSQL) and cost utility analyses (based on the HUI3 for the 
primary analysis and mapping of the OM8-30 to the HUI3 for the secondary analysis). If 
feasible, a longer-term time horizon based on decision-analytic modelling and populated from 
parameter estimates derived from the trial and from information from literature sources 
relating to long-term effects of hearing difficulties in children was proposed. A health 
economics plan was included within the SAP. Data analysis was conducted in STATA 
(version 13.1).35 For the within-trial analysis, no discounting was done as the trial duration 
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was 12 months.  A summary of the terms used within the economic analysis are presented 
below:  
 
Terms of interest.  
• Basecase39   - The main analysis, with no deviations to assumptions 
• Primary analysis  - The HUI-3 analysis from which the sensitivity analysis is 
undertaken 
• Secondary analysis - The analysis using PedsQL for CEA and mapping HUI-3 
from the OM8-30 
• Preliminary analysis  - Early analysis which informs approach but where outcomes 
are not reported.  
• Available data  - Uses all data regardless of missing components 
• Complete case  - Limits inclusion into the analysis to those individuals who 
reported figures for all components.  
• Multiple imputation40 - The missing data technique used which estimates additional 
sets of data based upon selected predictive variables.  
 
Costs 
Resource use and associated costs were calculated across the following broad categories: 
i. The acquisition costs of oral steroids (intervention cost), 
ii. Health and personal social care resource use at 5 weeks, 6 months and 12 months 
following randomisation,  
iii. Other resource use incurred by the family related to direct costs (e.g. OTC 
medications) and indirect costs (time off work and other duties to the care of the child 
as a result of ear problems at 5 weeks, 6 months and 12 months following 
randomisation. 
 
The resource use and associated costs were first examined in disaggregated categories (e.g. 
medications, community/primary care contacts) based on all available cases. 
 
Intervention costs 
Drug acquisition costs were based on the unit cost of a prescription of a 7-day course of oral 
soluble Prednisolone (5mg) based on the age-specific trial dosage, and weighted for the 
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number of children in each of the age groups (2-5 years and 6-8 years).  As the oral steroid 
was prescribed during a scheduled out-patient appointment, this appointment was not 
included.  
 
 
 
Individual patient level resource use and associated cost  
For NHS resource use, national average unit costs were applied from published sources 
including Unit costs of health and social care41, NHS reference costs42 and the British 
National Formulary.38  A summary of the Unit costs are provided in appendix 7. As GP visits 
were recorded separately;  to avoid potential double counting, we took a bottom up costing 
approach  to calculated  prescription costs in primary care using the cost of the medication 
prescribed and the pharmacist’s  time to dispense the medication. Based on an estimated 
assumption agreed with the trial team that each prescription item would take approximately 5 
minutes, we used used the PSSRU hourly rate for a pharmacist to calculate an average 
dispensing cost.  
All costs were recorded on 2015-16 prices in pound (£) sterling. Where a relevant unit cost 
could not be obtained, other published sources were consulted (e.g. previous Unit cost 
manuals, papers or NICE costing information obtained from previous economic analysis to 
inform national guidelines on OME were used with adjustment for inflation).43, 44   
 
Where parents had indicated OTC medication use but not given a cost, the mean cost was 
calculated based on an average price listed by a national pharmacy (Boots on-line45) and three 
national supermarkets (Asda, Sainsbury’s, and Tesco), where available. Where time taken off 
work was indicated, but no pay loss given, a national median daily wage of £70.07 was used 
(methodology taken from Manning et al. 2014);49 where pay loss was specified, this figure 
was used irrespective of the number of days taken off work reported.  Missed school days 
were described but were not costed separately to costing of days off work and additional 
childcare costs.   Where distance travelled was indicated the cost was calculated using the 
HM Revenue and Customs (HMRC) rate of £0.45 per mile.50 All sources of unit costs used to 
inform the calculation of family costs are reproduced in Chapter 4.  
Outcomes used in the economic analysis 
Trial outcomes use 
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The primary trial outcome measure of the trial (acceptable hearing achieved at 5 weeks as 
defined within the OSTRICH trial protocol) was used to calculate the cost effectiveness of 
the intervention. To examine the longer term cost effectiveness, an additional analysis of the 
incremental cost of achieving a successful hearing resolution was also conducted at 12 
months.  
 
Health outcome measures:  
HU13:  The parent-completed data from the HUI329, 51 collected at baseline, 5 weeks, 6 and 
12 months was used as the primary source of preference-based utility weights to generate 
quality adjusted life years (QALYs) for the primary cost-utility analysis.  The HUI3 is a well-
established preference based measure of HRQoL in childhood health conditions, covering 
eight dimensions (vision, hearing, speech, ambulation, dexterity, emotion, cognition and 
pain). Standard procedures recommended by the HUI3 developers were used to construct a 
multi-attribute utility score.  
 
OM8-30: Previous researchers have mapped OM8-30 scores to utility values on the HUI3 
scale and have found reasonably small mean absolute errors (MAEs).52 As this trial measured 
both OM8-30 and HUI3, it provided the opportunity to evaluate the generalisability of the 
existing mapping. We did this by correlating the mapped utility values on the HUI3 scale 
(obtained via the mapping formula from the OM8-30 facet scores) with the newly acquired 
HUI3 scores (all measures obtained by parent proxy). 
Mappings are applicable in future studies of all types that may not have the resources of a 
centrally funded trial to also acquire generic measures, and also to bring past studies into 
systematic review on a universal metric. It was anticipated that this work would contribute to 
the development and validation of a short form of the OM8-30 (the Q-14), which is likely to 
become a widespread standard in ENT and paediatrics.  
 
PedsQL: As the PedsQL was collected as one of the secondary outcome measures, the 
original protocol set out to compute utilities from the PedsQL.31  Whilst the PedsQL is a 
well-established measure of HRQoL, at present it cannot be used to calculate QALYs as it is 
not a preference-based measure. To overcome this challenge, several studies have produced 
mapping algorithms to estimate health utilities such as the EuroQol 5D-Y (EQ-5D Y)53 and 
Childs Health Utility 9D (CHU-9D).54 The analysis was planned to be based on the mapping 
algorithm described by Khan et al.53 However, this would depend on the feasibility of using a 
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sub-set of OSTRICH participants eligible to be mapped against the age-range of the EQ-5D 
Y population (minimum age of 8 years).  Given the small number of children in the trial 
population in this age group, the PedsQL data were not mapped but used directly to provide a 
secondary cost effectiveness analysis based on the incremental cost per point difference in 
PedsQL score at 12 months in order to capture parent reported HRQoL changes in their child. 
Analysis of costs 
Costs for each participant were calculated by multiplying their use of each resource item by 
the relevant unit cost. As no baseline costs were collected, the impact of baseline imbalance 
could not be considered, i.e. costs were assumed to be the same for each group at baseline. 
Costs were summated for each assessment point and then compiled to provide an aggregated 
cost per group across the trial duration. A total mean cost per participant was computed for 
each group, with differences assessed using a linear regression model approach to identify 
whether the intervention was a significant predictor of cost. The mean difference in cost is 
reported by the coefficient estimate of the binary treatment group covariate, with 95% CIs 
reported. 
Analysis of health economic outcomes  
The output from the analysis of the primary outcome measure was used within the cost 
effectiveness analysis. To maintain consistency with the statistical analysis, non–imputed 
data was used for the base case; with multiple imputed (MI) data used within the sensitivity 
analysis.  Given the impact of missing data during follow up, MI was used for the base case 
of all subsequent secondary cost effectiveness analysis and cost-utility analysis (CUA).  The 
secondary analysis using the PedsQL data was again adjusted for the same covariates used in 
the clinical effectiveness analysis with the base-case based on MI imputed data.  For the 
CUA, QALYs were derived from the utility values reported from the HUI3.  As the 
preliminary analysis highlighted small differences in baseline utility, utility scores were also 
adjusted by baseline utility and used within the base-case CUA. 
 
Utilities from the HUI were calculated for each participant at each assessment point. Utilities 
were then converted into QALYs for each participant using the area under the curve (AUC) 
method which assumes linear interpolation between each time-point. Differences in QALYS 
from baseline to 12 months were summarised as total mean QALY gain between placebo and 
oral steroid group and 95% CIs reported, with linear regression used to test for differences 
between groups.  A similar approach was used to derive QALYs from the mapped utilities 
derived from the OM8-30 to the HUI3.  
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Missing data 
Considerable effort was devoted to minimising missing data. Research nurses were trained in 
data collection and the questionnaires filled out by them were designed to minimise the 
amount of missing information.  
 
The general problems associated with missing data are particularly relevant to health 
economic analysis, especially in a within-trial analysis where costs and QALYs are based on 
cumulative measures collected over the trial duration. Missing items relating to health care 
service usage may undervalue the total cost whilst missing outcome data may bias effects as 
those individuals without information may be systematically different to those for whom all 
information is observed.  
 
The use of complete case analysis provides a useful first exploratory stage of an economic 
evaluation.  However, according to recommended good practice38, 41 it is not sufficient for a 
robust base case analysis where missing data is identified.  The health economic analysis plan 
took this into consideration and proposed multiple imputation (MI) as an additional approach 
to support the complete case analysis.55 Measures which include multiple components over 
time are particularly susceptible to missing data issues, for these outcomes MI analysis will 
be the central approach.  
 
The decision (and appropriate method) for missing data imputation was informed by 
conducting a descriptive analysis of resource use and outcome data by group at each 
assessment point. The pattern of missing data was examined to ascertain whether the missing 
data could be considered missing at random (MAR) in order to employ suitable MI methods.  
Complete case analysis and available analysis was conducted as an additional sensitivity 
analyses to explore the impact of different imputation methods on the base-case findings. 
 
The ‘MI’ command in STATA was used to impute missing data from the total costs and from 
the HUI3 data measures at baseline, 5 weeks, 6 months and 12 months.  Age, gender and site, 
as explained earlier in the methods chapter, were included as covariates in the imputation 
models for the CUAs. Costs and utilities were imputed using predictive mean matching as 
this allows sampling within the observed values and is less dependent on the assumptions of 
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normality. Fifteen data sets were created, based on the level of missing data. These imputed 
data sets were used to produce a summary statistic (i.e. mean cost and utility).  
To ensure consistency across the statistical and economic analysis, complete case analysis 
was used to inform the base-case analysis for the both primary and secondary cost 
effectiveness analyses of hearing resolution. The CUA, which includes the HUI3 and 
PedsQL, utilises the MI approach in the base-case analysis.  
 
Incremental cost effectiveness analysis (ICER) 
Two main incremental analyses were undertaken. The first comprised a cost effectiveness 
analysis (CEA) to calculate the incremental cost of achieving an acceptable level of hearing 
in one or both ears at 5 weeks; with additional analysis undertaken to assess cost 
effectiveness at 12 months. A secondary CEA investigated the incremental cost per 
improvement in PedsQL score.  The second incremental analysis was a CUA to assess the 
incremental cost per QALY - using the HUI3 to derive utilities gained as a result of oral 
steroid treatment at 12 months with secondary CUA conducted to assess the incremental 
QALY gained as a result of oral steroid treatment at 12 months based on utilities derived 
from mapping the OM8-30 to HUI3. 
Results of the comparative analyses of incremental costs and effects were expressed as 
ICERs. 
 
An ICER is calculated as: !"#$ = "& − "(#& − #( = Δ"Δ# 
 C& and E& represent the costs and effects of the intervention group and C( and E( the cost and 
effects of the usual care group, with ΔC and ΔE the incremental costs and effects of the 
intervention compared to usual care.  
 
This results in four potential scenarios which can be illustrated by the cost effectiveness (CE) 
plane (Figure 9). 
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Figure 8 Illustration of the cost effectiveness (CE) plane 
 
If the intervention is less costly (negative incremental costs) and produces more effect (e.g. 
positive incremental QALY gain); then the intervention is considered dominant to placebo 
and thus cost-effective (results would be located in the South-East Quadrant). Conversely, if 
the intervention is more costly (positive incremental cost) and produces less effect (negative 
incremental QALY gain), the intervention can be considered dominated by the placebo and is 
thus not cost-effective (results would be located in the North-West Quadrant). In these 
scenarios, no ICER is reported. 
 
In the third possible scenario the intervention is more expensive (positive incremental cost) 
but produces more effect (positive incremental QALY gain, result located in the North-East 
Quadrant)). In the fourth scenario, the intervention would be less costly but produces less 
effect (negative incremental QALY gain, result located in the South-West Quadrant). In these 
latter scenarios, the ICER is computed to assess whether the net incremental health gain (or 
loss) is worth the incremental cost (or cost saving). For the CUA, NICE guidelines regarding 
the societal willingness to pay (WTP) threshold were used.56 Generally, an ICER below 
£20,000 per QALY is considered cost-effective. 
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For the ICER produced by the CEA, descriptions of the probability (%) of being within 
notional WTP thresholds of £1,000, £2,500 and £5,000 per acceptable hearing loss achieved 
were used.  
Health economic sensitivity analyses  
Deterministic sensitivity analyses were undertaken on the cost effectiveness and CUA to 
assess the extent to which changes made to different parameter values and assumptions affect 
the results.  The one-way sensitivity analyses undertaken are summarised below. 
1. Cost effectiveness analysis (cost per hearing resolution at 5 weeks + cost per 
improvement in PedsQL at 12 months) 
• Available and MI (for cost per hearing resolution at 5 weeks) or complete cases (cost 
per improvement in PedsQL) in the analysis of costs and outcomes, 
• Adjustment of costs and outcomes by upper and lower bound values (based on 95% 
CIs) for net costs and benefits. 
 
 
2. Cost-utility analysis (cost per QALY gain at 12 months)  
• Use of available and complete cases in the analysis of costs and outcomes, 
• Adjustments of costs and outcomes (base–case results) by upper and lower bound 
values (based on 95% CIs) for net costs and benefits, 
• Utilities derived from mapping the OM8-30 to HUI3. 
Probabilistic sensitivity analysis was undertaken to investigate the combined effect of 
uncertainties associated with the differences between costs and outcomes on the results of the 
economic evaluation for the primary cost effectiveness analysis (at both 5 weeks and 12 
months) and cost-utility analysis (cost per QALY gain at 12 months using the HUI3 utilities). 
Bootstrapping simulations, based on 5,000 re-samples, were used to characterise the joint 
distribution of costs and outcomes, illustrated using CEPs  for the primary cost effectiveness 
analysis and CUA.  Cost effectiveness acceptability curves (CEACs) were produced to 
express the probability that the intervention is cost-effective at different WTP thresholds, as 
explained above.  
 
Results 
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Costs 
The cost of a 7-day course or oral soluble Prednisolone, weighted for the different 
prescription dosage based on age was estimated to be £59 (taking into account the 
prescription dispensing cost, this figure rises to £62). 
The frequency and cost of healthcare service use at 5 weeks and then over 12 months for the 
placebo and oral steroid groups are reported in Tables 20 and 21. Overall, no significant 
differences in resource use or costs were found for any of the categories of health service 
usage between the placebo and oral steroid groups.  Inclusion of resource use and costs to the 
family did not change these results. 
Table 20 Summary of resource cost 
Component  Unit Costs (£) 
Soluble Prednisolone tablets  
Ages 2-5 20mg daily 50.76 
Ages 6-8 30mg daily  76.14 
GP  
Normal hours 46.00 
Out of hours 68.65 
Home visit 75.40 
Telephone call 11.25 
Medication  
Prescription dispensing cost  3.50 
Nurse  
Practice Nurse 22.50 
Community Nurse 39.00 
Accident and Emergency 136.00 
Outpatient Hospital Clinic 146.01 
Inpatient Hospital stay  2,385.27 
NHS Speech and Language 
Therapy  
Community based 89.00 
Hospital clinic 67.00 
NHS Direct 7.90 
Interventions  
Ventilation tubes 944.00 
Tonsillectomy 1326.00 
Adenoidectomy 1238.00 
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Auto-inflation device 5.88 
Hearing aid 132.20 
Social costs   
Mileage costs (per mile) 0.45 
Missed work cost  70.07 
 
Table 21 provides a summary of the total NHS costs for the placebo and oral steroid group at 
5 weeks and 12 months, using non-imputed, complete case for the base case and MI 
presented for use in the sensitivity analysis. At 5 weeks the oral steroid group was found to 
have a significantly higher health care cost compared to placebo for the base case with a 
similar picture seen when MI data were considered. At 12 months, costs were higher in the 
steroid group when compared to placebo across both imputation approaches but did not reach 
statistical significance.   A similar picture (i.e. the oral steroid group incurred higher costs 
compared to placebo which were statistically significant at 5 weeks but not at 12 months 
when costs to the family are included (Table 21).  When differences in mean costs per patient 
in the oral steriod group compared to placeo, oral steriods were consistently more expensive 
compared to placebo. 
 
Table 21 Summary of total mean cost per patient for placebo and oral steroid groups 
based on different data treatment approaches (including intervention cost for the oral 
steroid group) 
 Placebo 
(£) 
Oral steroid 
(£) 
Difference1 (£) 
(95% CIs) 
p value 
5 weeks ( health care  costs) 
Complete cases 36 78 49 (6,71) 
0.020 
Multiple 
imputed 35 80 
42 
(11,74) 
0.009 
12 months (health care costs) 
Complete cases 775 935 177 (-132, 487) 
0.261 
Multiple 
imputed 794 934 
145 
(-136,426) 
0.309 
5 weeks (Societal costs)  
Complete cases 46 84 35 0.043 
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(1, 69) 
Multiple 
imputed 
44 86 40 (9,71) 0.012 
12 months (Societal costs)  
Complete cases 
851 998 
160 
(-181, 500) 
0.356 
Multiple 
imputed 
867 987 114 (-178,406) 0.442 
1As summarised in the methods section of analysis of costs and outcomes; the difference 
in mean cost per patient between oral steroid and placebo (and resulting 95% CIs and p 
value presented) is based on the results of the OLS regression. 
 
 
 
 
Outcomes 
Hearing resolution at 5 weeks and 12 months 
The value for the clinical outcome used in the base case was the 7.1% difference in 
acceptable hearing loss between oral steroid and placebo at 5 weeks and 5.8% difference at 
12 months.  
 
PedsQL 
The mean score in PedsQL between placebo and oral steroid groups over 12 months is shown 
in Table 22, based on the MI data. At 12 months, the mean difference in improved PedsQL 
between oral steroid and placebo (when baseline is controlled for) showed a small, non- 
statistically significant gain in favour of oral steroid.. The results based on a complete case 
analysis for the PedsQL score is summarised in Appendix 6. 
 
Table 22 PedsQL scores over 12 months by group using multiple imputation 
 Placebo  
 
Oral steroid  
 
Mean 
Difference*  
( 95% CI )  
 P value 
PedsQL 
Baseline 79.2 78.8 -0.20 0.899 
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(-3.25,2.86) 
Week 5  80.3 79.9 -0.20 (-3.68,3.28) 0.909 
6 months 79.8 79.8 0.67 (-3.02,4.36) 0.722 
12 months  82.2 83.1 1.18 (-2.27,4.62) 0.502 
PedsQL score 
over 12 months 80.5 80.6 
0.66 
(-1.37,2.69) 0.522 
*All mean differences account for the baseline covariates of age, gender and site. The area under the curve 
approach includes a baseline PedsQL covariate. 
 
Quality adjusted life years 
Table 23 reports the HUI3 utilities and QALY gains by group over 12 months based on the 
MI approach with baseline adjustment used for the base case.  The HUI3 health index reports 
better health as higher values. Were the oral steroid group to experience increased QoL 
following the intervention the net benefit would be a positive QALY figure, and vice versa. 
Overall, there were small numerical differences in QALY gain in favour of placebo compared 
to oral care for both unadjusted and adjusted outcomes. In all instances, the difference in 
utilities at each assessment point and subsequent QALY gain at 12 months between placebo 
and oral steroid group are not statistically significant. The results based on different data 
approaches are presented in Appendix 8. 
 
Table 23 Utilities and QALY gains at 12 months using multiple imputation 
  Placebo  
 
Oral steroid  
 
Mean Difference  
( 95% CI )  
 P value 
HUI3 Utilities 
Baseline 0.743 0.760 0.013 (-0.033, 0.060) 0.568 
Week 5  0.771 0.763 -0.006 (0.053,0.041) 0.792 
6 months 0.833 0.822 -0.010 (-0.053, 0.033) 0.640 
12 months  0.835 0.851 0.016  (-0.026, 0.057) 0.453 
QALYs     
Unadjusted 
QALYS 0.814 0.811 
-0.008 
 (-0.036, 0.021) 0.592 
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Baseline 
Adjusted 
QALY1 
0.070 0.051 -0.015  (-0.054, 0.023) 0.448 
  
QALYs generated from mapping the OM8-30 to HUI3 
Table 24 presents the mapped OM8-30 to HUI3 figures across each of the collection time- 
points and the resulting unadjusted and adjusted AUC results. The HUI3 averages report that 
the cohort, both the placebo and the intervention group, were of broadly good health. The 
high HUI3 figures represent a ceiling effect which diminishes the scope for improvements. 
The baseline figure reported for the oral steroid group is lower than the placebo group. Both 
groups showed improvement over time, the unadjusted QALY scores suggested that the 
placebo group had better health at the 12 month mark. Accounting for the disparity at 
baseline offered an insignificant incremental improvement in QALY for the oral steroid 
group 0.004.  
Table 24 Utilities and QALY gains at 12 months including values imputed from 
mapping OM8-30 data to HUI3 utilities 
 Placebo  
 
Oral Steroid  
 
Mean 
Difference  
( 95% CI )  
 P value 
HUI3 mapped  Utilities 
Baseline 0.964 0.956 -0.008 (-0.016, -0.001) 0.034 
Week 5  0.969 0.965 -0.005 (-0.013, 0.004) 
0.279 
 
6 months 0.994 0.991 -0.003 (-0.012,0.006) 
0.553 
 
12 months  0.994 0.990 -0.005 (-0.014, 0.004) 
0.286 
 
Unadjusted 
QALYS 0.986 0.983 
-0.004 
(-0.011, 0.003) 
0.258 
 
Adjusted 
QALY1 0.023 0.026 
0.004 
(-0.002, 0.011) 
0.199 
 
 
The impact of using a complete case analysis is summarised in Appendix 9. 
 
Incremental cost effectiveness analysis  
Table 25 presents the incremental cost effectiveness analysis at 5 weeks. The base case 
analysis showed an incremental cost of £546 to achieve an additional hearing resolution. This 
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additional hearing resolution finding is a result of statistically significant differences in costs 
and statistically and clinicially insignicant differences in  hearing resolution in  oral steroids 
compared to placebooutcome and as such, the ICER should be interpreted within this context. 
In the sensitivity analysis, oral steroids were dominated by placebo (i.e. had higher cost and 
lower net benefit) on 2 of the 4 scenarios(when costs or outcomes were at the lower bound 
95% CI); this suggests the findings were not robust to changes in these parameters.  
 
 
Table 25 Base and case sensitive analysis for the primary cost effectiveness analysis 
(incremental cost per acceptable hearing resolution at 5 weeks) 
Parameter  Incremental 
cost (£) 
Incremental 
effect 
ICER (cost (£) per 
additional 
resolution) 
Base case  39 7.1% £546 per additional hearing resolution 
Upper 95% bound1 of net 
cost 71 16.4% 
£432 per additional 
hearing resolution 
Upper 95% bound1 of % 
successful hearing resolution 
Upper 95% bound1 of net 
cost 71 -0.0% 
Oral steroid 
dominated by 
placebo Lower 95% bound1 of % 
successful hearing resolution  
Lower 95% bound1 of net 
cost 6 16.4% 
£37 per additional 
hearing resolution 
Upper 95% bound1 of % 
successful hearing resolution 
Lower 95% bound1 of net 
cost Upper 95% bound1 of % 
successful hearing resolution 
6 -0.0% 
Oral steroid 
dominated by 
placebo 
1 Based on the upper and lower confidence intervals from the base case costs and covariate adjusted clinical 
resolution gain at 5 weeks. 
 
 
The results on the bootstrapped replications are presented in the cost effectiveness plane 
(Figure 10).  Whilst point estimates are displayed in all four quadrants of the CE plane, the 
greatest density of the point estimates reflect the scenarios that oral steroid could be 
considered cost-effective (i.e. the North-East quadrant) on the cost effectiveness plane or oral 
steroid is dominated by placebo i.e. higher costs, less effect (represented by the North-West 
quadrant). 
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Figure 9 Cost effectiveness plane of incremental costs per acceptable hearing resolution 
at 5 weeks 
 
The cost effectiveness acceptability curve is presented in Figure 11.  This showed that, at a 
WTP threshold of £1,000, £2,500 and £5,000 per acceptable hearing resolution achieved,  the 
probability of oral steroids being a cost-effective option at 5 weeks was 41%, 60% and 65% 
respectively. 
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Figure 10 Cost effectiveness acceptability curve incremental cost per acceptable hearing 
resolution achieved at 5 weeks 
 
Table 26 shows the results at 12 months.  The base case analysis indicates that the 
incremental cost of every additional hearing resolution was £3,052 after 12 months.  When 
costs and outcomes are varied, uncertainty again arises in the results due to the statistically 
non-significant differences in costs and treatment benefit with wide CIs.  
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Table 26 Base case and sensitivity analysis for the primary cost effectiveness analysis 
(incremental cost per acceptable hearing resolution at 12 months) 
Parameter  Incremental 
cost (£) 
Incremental 
effect 
ICER (cost (£) per 
additional hearing 
resolution) 
BASE CASE 177  
5.8% £3,052 per additional 
hearing resolution 
Upper 95% bound1 of net 
cost 
487 17.2% £2,831 cost per 
additional hearing 
resolution Upper 95% bound1 of % 
successful hearing resolution 
Upper 95% bound1 of net 
cost 
487 -5.5% Oral steroid 
dominated by 
placebo Lower 95% bound1 of % 
successful hearing resolution  
Lower 95% bound1 of net 
cost 
-132 17.2% Oral steroid 
dominates placebo 
Upper 95% bound1 of % 
successful hearing resolution 
Lower 95% bound1 of net 
cost 
Lower 95% bound1 of % 
successful hearing resolution 
-132 -5.5% £2,400 saved per 
reduction in 
adequate hearing  
1 Based on the upper and lower confidence intervals from the base case costs and covariate adjusted clinical 
resolution gain at 12 months. 
 
Figures 12 and 13 present the CE plane and CEAC to illustrate the incremental cost of 
achieving an acceptable hearing resolution at 12 months. Similar to the 5 week results, results 
are spread across all four quadrants. There is a 12%, 46% and 70% probability of oral 
steroids being a cost-effective option at WTP thresholds of £1,000, £2,500 and £5,000, 
respectively.  
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Figure 11 Cost effectiveness plane of incremental cost per acceptable hearing resolution 
at 12 months 
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Figure 12 Cost effectiveness acceptability curve - incremental cost per acceptable 
hearing resolution achieved at 12 months 
 
When the analysis was extended to reflect a limited societal perspective, the results remained 
consistent with the analysis based on an NHS perspective (see Appendix 10).   
 
Cost-utility analysis  
Table 27 presents the findings from the primary CUA. The base case analysis shows that that 
oral steroid treatment was dominated by placebo, with oral steroids costing an additional 
£145 with a net loss of 0.015 QALYs per child treated. As shown earlier in Tables 21 and 23, 
neither differences in costs or QALYs were statistically significant with only small, 
numerical differences in both measures. The uncertainty surrounding these findings is 
emphasised by the results of the sensitivity analyses undertaken. Complete case analysis 
suggests that oral steroid treatment yields an ICER of £22,882. Varying the parameters for 
both costs and outcomes further highlights the variability in the results. 
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Table 27 Results from the base case and sensitivity analysis for the primary cost-utility 
analysis (incremental cost per QALY gain at 12 months) 
Parameter  Incremental 
cost  (£) 
Incremental 
effect 
ICER 
BASE CASE (values using 
multiple imputed costs and 
QALYs) 
145 -0.015 
Oral steroid 
treatment 
dominated by 
placebo 
Complete cases 389 0.017 £22,882 
Upper 95% bound of net 
cost1 426 0.024 
£ 17,750 
Upper 95% bound of QALY 
gain1 
Upper 95% bound of net 
cost1 426 -0.054 
Oral steroid 
treatment 
dominated by 
placebo 
Lower 95% bound of  QALY 
gain1 
Lower 95% bound of net 
cost1 -136 0.024 
Oral steroid 
treatment 
dominates placebo Upper 95% bound QALY 
gain1 
Lower 95% bound of net 
cost1 -136 -0.054 
£2,518 saved per 
QALY lost 
 
1 Based on the upper and lower confidence intervals from the base case costs and QALY gain at 12 months. 
 
 
Based on the bootstrapped replications, this uncertainty is clearly illustrated in the cost 
effectiveness plane (see Figure 14). The distribution of results across all four quadrants is 
evident with greatest density reflecting the scenarios that oral steroid is dominated by placebo 
(i.e. less effect, more costs, represented by the North-West quadrant).  
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Figure 13 Cost effectiveness plane of incremental cost per QALY gain at 12 months 
based on values imputed from multiple imputation 
 
The CEAC is depicted in Figure 15. The probability of oral steroid treatment being cost-
effective when compared to placebo at a £20,000 per QALY threshold is 17%, increasing 
slightly to 22% at a £30,000 per QALY threshold. 
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Figure 14 Cost effectiveness acceptability curve of incremental cost per QALY gain at 
12 months 
 
 
When the analysis was extended to reflect a limited societal perspective, the results remained 
consistent with the primary analysis (Appendix 11).  
 
Sub-group analysis 
As there was no evidence of significant treatment effect in the sub-group analysis undertaken, 
this was not further considered within the economic analysis. 
 
Secondary cost effectiveness analysis: Incremental cost per improvement in PedsQL at 
12 months 
Table 28 shows the 12 months CEA. The incremental cost of achieving a point improvement 
in PedsQL score at 12 months was £220 for the base case and this remained consistent when 
complete cases were examined. Again, these results were sensitive to changes in varying the 
costs and outcomes.  
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Table 28 Base case and one-way sensitivity analyses of incremental cost per point 
improvement in PedsQL score at 12 months 
Parameter  Incremental 
cost (£) 
Incremental 
effect 
ICER (cost (£) per 
point improvement) 
BASE CASE (values using 
multiple imputed costs 
and effects)1 
145 0.66 £220 
Complete cases 145 0.58 £250 
Upper 95% bound1 of net 
cost 
426 2.69 £158 per point increase in PedsQL Upper 95% bound
1 of point 
improvement in PedsQL 
score 
Upper 95% bound1 of net 
cost 
426 -1.37 
Oral steroids 
dominated by 
placebo  
Lower 95% bound1 of point 
improvement in PedsQL 
score 
Lower 95% bound1 of net 
cost 
-136 2.69 Oral steroids dominates placebo  Upper 95% bound
1 of point 
improvement in PedsQL 
score 
Lower 95% bound1 of net 
cost 
Lower 95% bound of point 
improvement in PedsQL 
score 
-136 -1.37 £99 saved per point reduction in PedsQL 
1. The base case PedsQL effect is baseline adjusted.  
 
 
Figures 16 and 17 display the CE plane CEAC curve. Again, this showed that point estimates 
were spread across all four quadrants.  The probability of oral steroids being cost-effective 
based on notional WTP thresholds of £1,000, £2,000 and £5,000 per point improvement in 
PedsQL score at 12 months was 50%, 51% and 51% respectively. 
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Figure 15 Cost effectivness plane of incremental cost per point improvement in PedsQL 
at 12 months 
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Figure 16 Cost effectiveness acceptability curve of incremental cost per point 
improvement in PedsQL score at 12 months 
 
 
Secondary cost-utility analysis: Incremental cost per QALY gain (based on utilities 
estimated from mapping OM8-30 to HUI3) 
Table 29 shows the sensitivity analysis for the mapped OM8-30 to HUI3 scores for the 
multiple imputation approach and the figures from the complete cases analysis. The base case 
approach found that there were insignificant differences between groups for both the 
incremental costs and effects. The base case ICER of £26,750 should be viewed in the 
context of the sensitivity analysis which finds estimates in each of the four cost effectiveness 
quadrants.   
 
Table 29 Results from the base case and sensitivity analysis for the secondary cost 
utility analysis (incremental cost per QALY gain at 12 months) 
Parameter  Incremental 
cost  (£) 
Incremental 
effect 
ICER 
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BASE CASE (values using 
multiple imputed costs and 
QALYs) 
107 0.004 £26,750 per QALY 
gain 
Complete cases 121 0.002 £60,500 per increase in QALY 
Upper 95% bound of net 
cost1 
362 0.011 £32,909 per QALY 
gain 
Upper 95% bound of QALY 
gain1 
Upper 95% bound of net 
cost1 
362 -0.002 Oral steroid 
treatment 
dominated by 
placebo 
Lower 95% bound of  QALY 
gain1 
Lower 95% bound of net 
cost1 
-148 0.011 Oral steroid 
treatment 
dominates placebo Upper 95% bound QALY 
gain1 
Lower 95% bound of net 
cost1 
-148 -0.002 £74,000 saved per 
QALY loss 
Upper 95% bound of QALY 
gain1 
1 Based on the upper and lower confidence intervals from the base case costs and QALY gain at 12 months. 
 
Exploration of longer-term cost effectiveness of the intervention  
The original protocol set out a third objective to explore the long-term cost effectiveness of a 
7-day course or soluble oral Prednisolone as a treatment for bilateral OME in children. The 
health economics plan contains a summary of the analysis proposed. If feasible and indicated 
by the initial trial results, a decision-analytic model would be developed to assess the longer-
term cost effectiveness of the intervention. Prior to this, and on receipt of the initial analysis of 
the clinical effectiveness results, a feasibility check of undertaking the modelling would be 
discussed with the OSTRICH team based on the following parameters: 
a) The intervention shows sufficient evidence of clinical effectiveness during the trial as 
indicated in the OSTRICH protocol that a 15 % absolute increase in the rate of resolution at 5 
weeks would represent a clinically meaningful benefit; 
b) The trial results (and supporting literature) provide a sufficiently robust source for the 
estimation of all data inputs attributed to the intervention compared to placebo 
c) The model can be realistically expected to produce plausible estimates of the longer-term 
costs and outcomes associated with intervention. 
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Preparatory work was undertaken including a rapid review of the economic literature and 
supplementary spot searches to identify suitable data inputs supplementary to the trial results 
to inform the model and a detailed modelling plan (Appendix 2). Published model-based 
analyses of comparable interventions faced considerable challenges regarding outcome 
differences and available input data.57 Similarly, the OSTRICH trial found no evidence of a 
statistically significant treatment effect or impact on health outcomes at 12 months.  Also, 
considering the paucity of evidence available within the literature on longer-term impact of 
OME and its management, the time horizon would be severely constrained to 2 years. Even 
within this shorter duration, no reliable means for estimating the likely persistence of the small 
and statistically non-significant clinical and health outcome (QALY) effects beyond 12 months 
could be found. 
 
The feasibility of modelling was fully discussed with the OSTRICH trial team and members 
of the TSC in light of the presentation of the initial clinical and cost effectiveness findings. The 
consensus was that conducting the model based analysis at this point was not feasible but this 
could be revisited in the future based on extending the meta-analysis reported in the Cochrane 
review to include the OSTRICH trial findings. On the basis of this further meta-analysis (i.e. 
whether there is stronger evidence on a significant treatment effect of the use of oral steroids 
on OME); this would provide more robust and reliable data to inform a model-based analysis.  
 
Conclusions 
The economic evaluation found oral steroids at 5 weeks cost more compared to placebo, and 
no significant treatment effect. Interpreting the results of the CEA in light of the clinical 
findings is crucial, particularly as the findings failed to demonstrate a statistically or clinically 
significant treatment effect. The base case CEA suggests that it would cost £546 to achieve 
an additional hearing resolution at 5 weeks with uncertainty demonstrated in the sensitivity 
analysis, however this finding should be fully considered within the context that there was no 
statistically significant difference in hearing resolution between the two groups. 
 
The base case incremental cost per QALY at 12 months estimated that oral steroids were 
dominated by placebo and oral steroids would not be considered a cost-effective option. 
However, there is again considerable uncertainty seen in the sensitivity analyses. The impact 
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of the joint uncertainty in cost and outcomes is illustrated by the CEA curve estimating a 17% 
and 22% probability of oral steroids being considered cost-effective based on a societal WTP 
threshold of £20,000 and £30,000 per QALY gain.  
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Chapter 5 Discussion and Conclusions 
Summary of main results 
A short course of oral steroids in children with symptoms of OME for at least 3 months, and 
proven significant bilateral hearing loss, was neither clinically nor cost effective. A greater 
proportion of children in the group randomised to oral steroids, compared to placebo, had 
achieved satisfactory hearing at 5 weeks (39.9% versus 32.8%, absolute difference of 7.1 
(95% CI: -2.8 to 16.8%), number needed to treat (NNT) = 14). However, this difference was 
not statistically significant. Secondary outcomes were consistent with the picture of a small or 
no benefit, and we found no subgroups who achieved a meaningful benefit from oral steroids. 
There was no significant increase in adverse events in the intervention group and we found 
no evidence to suggest important harms from taking oral steroids. 
 
The results of the primary CEA suggest that the incremental cost of achieving an additional 
hearing resolution at 5 weeks as a result of oral steroid treatment was £690; this increased to 
£3,052 at 12 months. However, the overall health economic analysis is more complex, with 
differences in costs and outcomes at 12 months being small and not statistically significant, 
and the CUA (incremental cost per QALY gain at 12 months) suggesting that oral steroids 
are dominated by placebo (i.e. less effective and more expensive). 
 
We did, however, identify a resolution of hearing in those allocated to the placebo group in 
nearly a third by 5 weeks, more than half at 6 months, and more than 60% at 12 months. 
These high rates of resolution may be useful in shared decision making approaches to 
discussions concerning treatment options, including watchful waiting, with carers of children 
who have OME.  
 
Strengths and limitations 
OSTRICH is the first randomised controlled trial of oral steroids for OME, and one of only a 
few OME trials that used audiology-assessed resolution of hearing as the primary outcome. 
We found that the oral steroid and placebo group had different trajectories in tympanometry 
resolution over time, but no difference in functional health status or hearing, underlying the 
importance of functional and patient reported outcomes in addition to proxy measures. The 
hearing tests we used are relatively objective, related to resolution of the underlying 
pathology, related to functional status, and deemed a key outcome by our PPI representatives. 
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Clinicians, participants, parents, audiologists and members of the research team were all 
blind to intervention allocation, and we used matched placebos to help maintain blinding. We 
used remote, independent randomisation, and there was no indication of breaches in 
allocation concealment. Participants were recruited from a range of different hospital and 
audiology settings across the UK, all met strict inclusion criteria including having symptoms 
for at least 3 months and audiology confirmed significant hearing loss. Poor sound-proofing 
of audiology testing rooms could affect the quality of audiology data. However, all sites 
received extensive training and monitoring, and over 60% of patients were recruited in 
university/teaching hospital sites, so we believe that this is unlikely to have been a problem in 
this study. We measured many important secondary outcomes, including insertion of 
ventilation tubes and effect on QoL and functional health status using well-validated 
instruments. 
 
The trial was adequately powered to detect a 15% difference in recovery at 5 weeks, and is 
the largest trial of oral steroids for OME that has ever been conducted. However, more 
children than anticipated recovered by 5 weeks spontaneously (20% was used in the sample 
size calculation but the actual rate in the placebo group was 32.8%) leading to the possibility 
of a Type II error. We were able to follow participants for up to 12 months and achieved high 
follow-up rates (over 90% at 5 weeks and 6 months, and close to 90% at 12 months). 
Reported adherence to trial medication was also high, suggesting that lack of effect was not 
caused by poor adherence to treatment. 
 
The resource use questionnaire allowed participants to provide either a precise figure or a 
range, which resulted in some analytical challenges, and there were some differences in the 
way resource use data were recorded at 5 weeks and 6 and 12 months.  Slower than 
anticipated recruitment resulted in the need to take a pragmatic decision to not collect routine 
health record data. As a result, we were not able to validate self-reported healthcare 
consultation data or collect baseline resource use data. This lack of baseline resource use data  
made it impossible for us to assess  any potential baseline imbalance in resource use and take 
this into account in the base case and sensitivity analyses.  
 
We used a robust preference-based HRQoL measure (HUI3) and the additional exploration of 
the impact of using alternative approaches (mapping of the OM8-30) which has already been 
investigated in detail within a comparable patient population.52 Whilst there is evidence that 
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the HUI3 can be used to collect self-reported HRQOL directly from children 5 years and 
above51,  the majority of children were too young to provide direct child-based HRQoL, and 
we therefore had to rely on parent-proxy reporting, which has its own biases.58   
Generalisability 
Participants were recruited from 23 hospitals and audiology clinics in Wales and England. 
Sites included large teaching hospitals, children’s hospitals and smaller general hospitals. 
Although only 38% of those assessed for eligibility were included in the trial, the main 
reasons for not being included was not meeting the trial inclusion/exclusion criteria (in 
particular, not having bad enough, objectively measured hearing loss). Therefore, our results 
are likely to be generalisable to the population meeting the inclusion criteria for this trial (i.e. 
symptoms of OME for at least 3 months and clinically important bilateral hearing loss). Most 
children included in the trial were ethnically white, and so our results may not be 
generalisable to all ethnic groups. 
 
The majority of children included in the trial (63% of 2-5 year olds and 69% of 6-8 year olds) 
had mild hearing loss (26-40 dBHL) and therefore our results may not be generalisable to 
children with more moderate hearing loss, although we did not see any evidence of a 
beneficial effect in the sub-group with more moderate hearing loss. Furthermore, it is 
possible that children who did not meet our inclusion criteria (those with Downs Syndrome or 
unilateral hearing loss for example) may have responded differently. 
 
We recruited from secondary care sites (hospitals and audiology clinics) and therefore we 
need to be cautious about generalising these findings to a primary care setting. However, 
there is no reason to believe that the results are likely to be very different for children who 
meet the same criteria (including symptoms for at least 3 months and demonstrable hearing 
loss), but are identified in primary care, especially as the majority had mild hearing loss. 
Interpretation 
The point estimate for our measure of effect suggests a small benefit from oral steroids, in 
terms of resolution of hearing at 5 weeks. However, the CI crosses the null and we therefore 
cannot exclude no effect or even a harmful effect. Whilst no formal threshold exists for the 
WTP for an additional hearing resolution achieved, Williamson et al (2009) used a notional 
WTP threshold of £1,000 per OME cured.19 Using a similar notional value, oral steroids 
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would have an 85% and 62% probability to be cost-effective at 5 weeks and 12 months 
respectively. 
 
The latest update of the Cochrane review on oral or topical steroids for OME (last search 
August 2010) identified three trials (108 participants) of oral steroids versus placebo which 
suggested a benefit from oral steroids, but did not demonstrate a statistically significant 
finding.15 The review also identified five trials (409 participants) comparing oral steroids plus 
antibiotics with antibiotics alone, and found that the inclusion of oral steroids with antibiotics 
resulted in a statistically significant benefit in terms of resolution of OME. Studies included 
in the systematic review were short-term, underpowered, often had poorly described 
inclusion criteria and/or did not assess hearing at the time of inclusion, used ears rather than 
children as the unit of analysis, and used intermediate outcome measures, such as 
tympanometry results, rather than improved hearing. No other cost effectiveness studies of 
oral steroids for OME were identified. However, despite the poor quality of the prior 
evidence, the results are similar and suggestive of a small benefit from oral steroids. Whether 
such a small benefit is clinically important is another question. Our point estimate suggests a 
NNT of 14, which is not dissimilar to other medical interventions (e.g. NNT=15 for nicotine 
replacement therapy for smoking cessation59 and could justify use of a low-cost and safe 
intervention to reduce the burden of an important problem like significant hearing loss. We 
found little evidence to support the belief that a short course of oral corticosteroid therapy is 
associated with significant risks, either from our review of the literature or from the adverse 
effect and safety data from our study. A subsequent trial that found oral steroids and oral 
steroids followed by intranasal steroids compared resolved OME more than watchful waiting 
at six weeks, but by three months, this advantage disappeared.60 The American Academy of 
Otolaryngology—Head and Neck Surgery Foundation (AAO-HNSF) and the American 
Academy of Pediatrics (AAP), informed by the flawed studies in our review, recommended 
against oral steroids for OME.61 Despite this, adults with diagnosed with OME are more 
likely to be prescribed oral steroids than those without.62 
 
A review of surgical treatments of OME found that ventilation tubes improved hearing and 
time to resolution of OME, but did not improve speech, language or other functional 
outcomes compared with watchful waiting or myringotomy, and that tubes increased the rate 
of otorrhoea and tympanosclerosis.63  
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An overview of studies found that OME diagnosed by tympanometry of unknown duration 
had 28% spontaneous resolution by 3 months (95%, CI 14-41%), rising to 42% by 6 months 
(95% CI, 35-49%).6 In the OSTRICH trial we found higher rates of hearing resolution 
associated with OME.  
 
Conclusions 
Implications for healthcare 
OME is a common cause of hearing loss in children which results in a significant burden on 
children and their families, and accounts for considerable workload for primary care and ENT 
clinicians. It continues to be the most common reason for childhood surgery despite reported 
reductions in the number of ventilation operations.9 This trial has produced unique data about 
the generally favourable natural history of problems associated with OME that have lasted 3 
months or more in children who have proven bilateral hearing loss, and this data will be of 
great use to clinicians and parents in making decisions about treatment options. The 
Department of Health commissioned ‘McKinsey’ report concluded that ventilation tube 
surgery was relatively ineffective and recommended reductions in use of this procedure. They 
suggested that the National Health Service (NHS) could save £21 million per year by 
reducing grommet insertion by a further 90%.11 
Evidence supporting the use of oral corticosteroids for OME remains unclear.  Updating the 
meta-analysis of evidence on oral steroids for OME with the results of OSTRICH may help 
reduce uncertainty further. However, our findings suggest that any benefits from oral steroids 
are likely to be small and of questionable clinical significance, and given evidence of no 
beneficial effect on functional health status and HRQoL, we cannot currently recommend 
their routine use based on these findings. The data reported in this trial are the best available 
data on the effects of oral steroids in children with OME, and can be used to help inform 
discussions between parents and clinicians about the possible use of oral steroids for OME. In 
addition, the information on the natural course of the condition provided by OSTRICH could 
help inform decisions about which treatment options, including ‘watchful waiting’, parents 
might prefer. 
Recommendations for research 
We do not feel that further empirical studies addressing the same question are warranted. 
However, although we did not find any evidence of benefit amongst sub-groups, we were not 
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powered for these analyses and meta-analysis and further studies could help identify whether 
oral steroids are likely to be effective in certain sub-groups. 
 
Our trial has provided key data that can help inform a shared decision making approach in the 
management of OME. Studies exploring the optimal ways of sharing natural history and 
intervention effect data with parents, as well as further evaluations of alternative pathways, 
will help improve the management of this common and important problem. 
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Appendices 
Appendix 1 Proposed modelling plan 
 
Aim of analysis: To estimate the cost effectiveness of oral steroids + current standard 
practice versus standard practice in the treatment of persistent bilateral OME in children. 
Population:  Eligible children aged 2-8 years with symptoms of hearing loss for at least 3 
months attributed to OME referred to NHS secondary care (ENT outpatient or paediatric 
audiology and vestibular medicine (AVM) clinics. Entry criteria for the model would reflect 
the OSTRICH trial inclusion criteria.  
Sub-groups:  No sub-groups are considered in the health economic analysis 
Interventions:  Short course of oral steroids as per the OSTRICH protocol 
Comparator:   No treatment or other technologies  
Outcomes:  Successful hearing resolution, treatment related morbidity, health-related quality 
of life. 
Time Horizon: 24 months.  Due to the lack of literature available on the longer-term 
outcomes associated with OME and its treatment, this was agreed as the most plausible 
horizon that could be considered within the model. 
Analysis plan 
A decision tree model will be constructed in Microsoft Excel using Visual Basic Application 
(VBA). A decision tree was chosen as the most appropriate model structure to reflect the 
clinical pathway, based on discussion with the OSTRICH trial team and following review of 
similar model-based analyses within a comparable population (Williamson et al 2009, 
Mohiuddin et al 2014); with the latter model used as the basis for adaption to the OSTRICH 
population. A schematic of the proposed model is set out in Figure 1. 
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Figure 1: Schematic of the OSTRICH model 
 
Pathway assumptions 
An eligible child will be assigned to either receive the steroid or the placebo for 1 week on 
model entry. After 4 weeks, the child will be reassessed to quantify the change in hearing loss 
and to determine whether hearing resolution was achieved or not. If hearing is not resolved, 
the next possible options are surgery, hearing aids, or watchful waiting (as hearing loss in 
children with OME can spontaneously resolve within 2 years). Surgery carries the risk of 
complications which can have a detrimental effect to patient quality of life and cause costs to 
the NHS and society. Repeat surgery may be required if hearing resolution is not achieved or 
the grommets fall out too early. Any treatment can be stopped at any time. 
While NICE guidelines (CG60, NICE 2008) recommend a third surgery option, this cannot be 
modelled using the available trial data as patients retrospectively report data at three individual 
time-points (5 weeks, 6 months and 12 months) and follow-up is not long enough to record 
third surgeries. It might be possible to obtain information regarding waiting list entries for third 
surgery at the third data capture point. Also, having already had two surgical interventions, we 
can assume that this surgery would take place in the future but have no way of gauging the 
outcome of this procedure. We also cannot predict what will happen whilst the patients are 
waiting for this third surgery, whether they will experience some hearing resolution while being 
monitored or whether their hearing will deteriorate. Therefore we will not speculate about the 
outcomes at this stage but rather will include surgery within an upper bound value of final costs 
for a sensitivity analysis.   
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Data inputs and sources 
In the first instance, the transition probabilities, appropriate costs and outcomes (including 
HRQoL and OME resolution) will be obtained from the OSTRICH trial data. Costs and 
outcomes will be accumulated over the model horizon of 24 months. Cost effectiveness of the 
steroid treatment will be calculated after 5 weeks, 6 months, 12 months and 24 months.  
Discounting will be applied in the base case analysis at 3.5%, with sensitivity analysis using a 
discount of 1.5% per annum for costs and outcomes, commensurate with NICE reference case 
(NICE 2013) for cost effectiveness at 24 months. 
Analysis 
In accordance with the within-trial OSTRICH economic analysis, two sets of base case 
analyses will be undertaken:  
• Incremental cost per successful hearing resolution achieved at 24 months 
• Incremental cost per QALY gained at 24 months 
 
Sensitivity analysis 
One-way sensitivity analyses will be undertaken to assess the extent of changing key 
parameters (e.g. utility values from the OSTRICH trial compared to literature based inputs) on 
the base-case results. Probabilistic sensitivity analysis will be conducted to characterise the 
joint uncertainty in parameter estimates. Cost effectiveness acceptability curves (CEACs) will 
be generated to depict the probability of the intervention being cost effective at different 
willingness-to-pay (WTP) thresholds.  
Literature sources 
A rapid review of the evidence was undertaken to gather suitable information to inform data 
inputs required for the model pathways and the sensitivity analyses (e.g. by considering 
different parameter variations reported in the literature compared to the OSTRICH trial results).  
Summary of rapid review 
The objectives of the review were: 1) To review the evidence of the cost effectiveness of oral 
steroids in the management of bilateral OME; and 2) To identify potential sources of 
information to inform a subsequent model based analysis.  
A PICO was constructed based on the OSTRICH trial population and intervention. We did not 
restrict for comparators in order to consider the full extent of the evidence e.g. if oral steroid 
had been compared to another technology such as intranasal steroids.  We considered both 
primary and secondary care settings. For outcomes, we considered all full economic 
evaluations (cost effectiveness, cost-utility, cost-benefit, cost-minimisation) and cost 
consequence analysis. Partial economic evaluations (e.g. where costs only were presented) 
were excluded from objective 1 but considered for informing objective 2 if relevant.   
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A search strategy was developed (available from the authors). Searches were undertaken using 
the following electronic databases: i) Pubmed (via NCBI), ii) Web of Science (via Thompson 
Reuters), iii) Scopus (via Elsevier), iv)  The Cochrane Library (via Wiley Online Library) 
which includes the Cochrane Database of Systematic Reviews (CDSR), the Database of 
Abstracts of Reviews of Effectiveness (DARE), the Cochrane Central Register of Controlled 
Trials (CCRCT), the Cochrane Methodology Register (CMR) Cochrane, v) Cumulative Index 
to Nursing and Allied Health (via EBSCO). In addition, reference lists were scanned and spot 
searches were undertaken to locate suitable evidence. No date or language limits were applied 
(Figure 2).  
 
Figure 2: Flowchart of rapid review search results 
 
 
n = 0 
Accepted for final review (objective 1) 
n=3 (comparable economic evaluations).n =1 (meta-analysis) 
 
n = 807 
Duplicate studies removed 
n = 2421 
Titles and/or abstracts screened with inclusion 
and exclusion criteria 
n = 2284 
Studies excluded due to irrelevancy 
n = 137 
Studies accepted for full text review and reference searching 
 
n =133 
Studies excluded using inclusion and 
exclusion criteria 
n = 3230 
Studies identified via electronic databases 
 
Pubmed:     513 
Web of Science:     429 
Scopus:     1959 
Cochrane:                    281 
CINAHL:                     50 
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For objective 1, no papers were identified. For objective 2, we identified three full economic 
evaluations that could provide suitable inputs for the OSTRICH model (Williamson et al 2009, 
Mohiuddin et al 2014, Mohiuddin et al 2015), alongside the NICE (2008) clinical guidance 
(CG60) for the surgical management of OME in under 12’s.  Another study (Petrou et al 2010) 
reported the economic evaluation within the Williamson et al 2009 report. We will use the 
Williamson et al report as the main source due to completeness of reporting.  
One Cochrane review (Venekamp et al 2016) was identified as a key source for potential 
clinical inputs from the literature. No suitable papers were identified to provide longer-term 
data inputs on health related quality of life/utilities.  
All parameters will be extracted from the relevant papers. As all the selected studies for 
objective 2 did not meet the full PICO criteria for OSTRICH, (i.e. different age population, 
setting or intervention), we will present and validate all parameters with the OSTRICH trial 
team and where applicable, use sensitivity analysis to take into account any parameter variation 
that could impact on the health economic results. Where the literature does not identify suitable 
parameters, further spot searches and/or clinical opinion may be used to inform parameters 
inputted into the model or any further assumptions made. A comprehensive table will be 
included in a final report of the model based analysis which documents all parameters used and 
their source.  
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Appendix 2 Subgroup analyses  
 
All analyses adjusted for site, child’s age group at recruitment (2-5, 6-8 years), and time 
since recruitment of 5 week assessment (days) 
 
1. Primary outcome by age group 
 Age 2-5 years Age 6-8  years 
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 85 (66.4) 43 (33.6) 36 (69.2) 16 (30.8) 
Oral steroids, n(%) 78 (62.4) 47 (37.6) 32 (55.2) 26 (44.8) 
Adjusted OR (95% CI) 1.21 (0.72 to 2.03) 1.74 (0.79 to 3.85) 
p=0.423 for comparison between two treatment effects (OR 1.21 vs. 1.74). 
 
2. Primary outcome by atopy  
 No Atopy  Atopy 
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 84 (66.1) 43 (33.9) 37 (69.8) 16 (30.19) 
Oral steroids, n(%) 70 (60.3) 46 (39.7) 40 (59.7) 27 (40.30) 
Adjusted OR (95% CI) 1.30 (0.77 to 2.21) 1.49 (0.68 to 3.29) 
p=0.653 for comparison between two treatment effects (OR 1.30 vs. 1.49). 
 
3. Primary outcome by antibiotics received for ear problems in last month  
 No Antibiotics   Antibiotics   
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 109 (65.3) 58 (34.7) 12 (92.3) 1 (7.7) 
Oral steroids, n(%) 101 (61.2) 64 (38.8) 8 (47.1) 9 (52.9) 
Adjusted OR (95% CI) 1.17 (0.74 to 1.85) 11.80 (1.18 to 117.80) 
p=0.038 for comparison between two treatment effects (OR 1.17 vs. 11.80) 
 
 
4. Primary outcome by number of previous episodes of OME 
 Previous OME episode First OME episode 
Randomised group No 
resolution 
resolution No resolution Resolution 
Placebo, n(%) 36 (72.0) 14 (28.0) 85 (65.4) 45 (34.6) 
Oral steroids, n(%) 39 (61.9) 24 (38.1) 71 (59.2) 49 (40.8) 
Adjusted OR (95% CI) 1.83 (0.79 to 4.21) 1.35 (0.80 to 2.29) 
p=0.639  for comparison between two treatment effects (OR 1.83 vs. 1.35 ) 
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5. Primary outcome by duration of problems due to this episode of OME 
 <12 months 12 months or more 
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 44 (63.8) 25 (36.2) 77 (69.4) 34 (30.6) 
Oral steroids, n(%) 35 (60.3) 23 (39.7) 75 (60.5) 49 (39.5) 
Adjusted OR (95% CI) 1.13 (0.54 to 2.33) 1.51 (0.87 to 2.64) 
p=0.555 for comparison between two treatment effects (OR 1.13 vs. 1.51) 
 
6. Primary outcome by previous tonsillectomy or adenoidectomy 
 No previous tonsillectomy/ 
adenoidectomy 
 Previous tonsillectomy/ 
adenoidectomy 
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 115 (67.3) 56 (32.7) 6 (66.7) 3 (33.3) 
Oral steroids, n(%) 102 (60.0) 68 (40.0) 8 (61.5) 5 (38.5) 
Adjusted OR (95% CI) 1.37 (0.88 to 2.13) 1.02 (0.06 to 17.33) 
p=0.913 for comparison between two treatment effects (OR 1.37 vs. 1.02 ) 
 
 
7. Primary outcome by household smoke present (> 5 hours a week) 
 No smoke present in home   Smoke present in home  
Randomised group No 
Resolution 
Resolution No Resolution Resolution 
Placebo, n(%) 81 (64.3) 45 (35.7) 40 (74.1) 14 (25.9) 
Oral steroids, n(%) 81 (59.6) 55 (40.4) 29 (61.7) 18 (38.3) 
Adjusted OR (95% CI) 1.21 (0.73 to 2.02) 1.81 (0.77 to 4.24) 
p=0.467 for comparison between two treatment effects (OR 1.21 vs. 1.81) 
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8. Primary outcome by season of recruitment  
 Spring (March to May)   Summer   Autumn   Winter  
Randomised group No 
Resolution 
Resolution No 
Resolution 
Resolution No 
Resolution 
Resolution No 
Resolution 
Resolution 
Placebo, n(%) 44 (71.0) 18 (29.0) 17 (58.6) 12 (41.4) 24 (80.0) 6 (20.0) 36 (61.0) 23 (39.0) 
Oral steroids, n(%) 34 (51.5) 32 (48.5) 14 (46.7) 16 (53.3) 22 (68.8) 10 (31.2) 40 (72.7) 15 (27.3) 
Adjusted OR (95% CI) 2.74 (1.20 to 6.23) 2.02 (0.67 to 6.03) 2.19 (0.60 to 7.99) 0.62 (0.28 to 1.37) 
p=0.076 for comparison between all treatment effects. 
 
9. Primary outcome by deprivation quintile 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Randomised 
group 
No 
Resolution 
Resoluti
on 
No 
Resolution 
Resoluti
on 
No 
Resolution 
Resoluti
on 
No 
Resolution 
Resoluti
on 
No 
Resolution 
Resoluti
on 
Placebo, 
n(%) 
20 (66.7) 10 (33.3) 121 (67.2) 59 (32.8) 33 (71.7) 13 (28.3) 32 (72.7) 12 (27.3) 28 (63.6) 16 (36.4) 
Oral steroids, 
n(%) 
15 (65.2) 8 (35.8) 110 (60.1) 73 (39.9) 28 (63.6) 16 (36.4) 26 (56.5) 20 (43.5) 32 (66.7) 16 (33.3) 
Adjusted OR 
(95% CI) 
0.94 (0.28 to 3.18) 1.25 (0.30 to 5.25) 1.37 (0.56 to 3.37) 1.91 (0.77 to 4.73) 0.92 (0.38 to 2.26) 
p=0.738 for comparison between all treatment effects 
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Appendix 3 Symptom score histograms by week (post randomisation) 
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Appendix 4 Parent reported adverse events from diary at 1 week post 
medication   
 Placebo 
N=170 
Oral steroids 
N=179 
No problems reported  148 (87.1) 154 (86.0) 
Children reported with having at least one problem 22 (12.9) 25 (14.0) 
Total number of problems 24 27 
RTI   
Phlegmy cough/cold/sneezing/ temperature/nosebleed/ 
conjunctivitis/itchy eyes/generally unwell 
2 7  
Headache 3 4 
Parotitis 1 0 
Ear pain on touch/ear ache 1 1 
Rash/pox/scarlet fever 2 0 
Flushed cheeks 0 1 
Digestion   
Increased appetite 4 3 
Low appetite 2 0 
Diarrhoea 2 2 
Constipation 1 1 
Nausea 0 1 
Behaviour   
Hyperactive 1 3 
Tired 1 1 
Frustration 1 0 
Change in behaviour 0 2 
Parent states child not hearing 1 0 
Sleep walking 0 1 
Other   
Finger infection    1 0 
Knee pain 1 0 
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Appendix 5 PedsQL scores over 12 months by group using complete case 
 
 Placebo  Steroid  Mean 
Difference*  
( 95% CI )  
 p value 
PedsQL 
Baseline 80.2 78.7 -2.19 (-5.77, 1.40) 0.231 
Week 5  81.5 79.9 -2.17 (-6.34, 2.00) 0.306 
6 months 80.7 80.1 -0.45 (-4.75, 3.84) 0.835 
12 months  82.5 82.7 0.26 (-3.77, 4.30) 0.898 
PedsQL score 
over 12 months 81.4 80.6 
0.58 
(-1.84, 3.00) 0.635 
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Appendix 6 Summary of Unit costs 
Component  Unit Costs 
(£) 
References  
Soluble Prednisolone tablets   
Ages 2-5 20mg daily 50.76 BNF 2015 38 - 28 tablets  
Ages 6-8 30mg daily  76.14 BNF 2015 38 - 42 tablets 
GP   
Normal hours 46.00 PSSRU 2016 41 
Out of hours 68.65 
PSSRU 2014 64 - cost £68.30 Inflated to 
January 2016 using inflation rate 1.005% 
Home visit 
75.40 
PSSRU 2016 41 - £46.00 for GP contact 
plus £29.40 (12 minute travel time @ 
£147 per hour) 
Telephone call 
11.25 
PSSRU 2016 41 – average of £7.90 
(Nurse) and £11.25 (GP) 
Medication   
Prescription dispensing cost  3.50  
Nurse   
Practice Nurse 
22.50 
PSSRU 2014 64  – 60 contacts per week, 
PSSRU 2016 41  weekly cost of £1,350 
Community Nurse 39.00 PSSRU 2016 41 
Accident and Emergency 136.00 NHS Reference Costs 2015/16 42  
Outpatient Hospital Clinic 146.01 NHS Reference Costs 2015/16 42   
Inpatient Hospital stay  
2,385.27 
NHS Reference Costs 2015/16 42   – 
Average LOS 1.2 days, excess day cost 
£371.96 
NHS Speech and Language 
Therapy  
 
Community based 89.00 PSSRU 2016 41 
Hospital clinic 67.00 PSSRU 2014 64 
NHS Direct 7.90 PSSRU 2016 41 
Interventions   
Ventilation tubes 944.00 NHS reference costs 2015-16 42 
Tonsillectomy 1326.00 NHS reference costs 2015-16 42 
Adenoidectomy 1238.00 NHS reference costs 2015-16 42 
Auto-inflation device 5.88 NICE guideline 65 
Hearing aid 132.20 Morris et al. 2012 66 
Social costs    
Mileage costs (per mile) 0.45 HRMC rate 
Missed work cost  70.07 Manning et al. 2015 49 
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Appendix 7 Utilities and QALY gains at 12 months using complete cases  
 
  Placebo  Steroid  Mean 
Difference  
( 95% CI )  
  p value 
HUI3 Utilities 
Baseline 0.778 0.756 -0.023 (-0.081, 0.035) 0.436 
Week 5  0.780 0.793 0.009 (-0.058, 0.075) 0.799 
6 months 0.841 0.822 -0.016 (-0.076, 0.043) 0.587 
12 months  0.852 0.851 0.000 (0.053, 0.054) 0.991 
QALYs     
Unadjusted 
QALYS 0.826 0.819 
-0.006 
(-0.056, 0.043) 0.801 
Baseline 
Adjusted 
QALY1 
0.048 0.063 0.017 (-0.033, 0.066) 0.503 
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Appendix 8 Utilities and QALY gains at 12 months including values 
imputed from mapping OM8-30 data to HUI3 utilities complete cases  
 Placebo  Steroid  Mean Difference  
( 95% CI )  
 p value 
HUI3 mapped  Utilities 
Baseline 0.965 0.956 -0.009 (-0.019, 0.000) 0.053 
Week 5  0.971 0.964 -0.008 (-0.019, 0.002) 0.126 
6 months 0.996 0.988 -0.006 (-0.017, 0.005) 0.261 
12 months  0.997 0.989 -0.008 (-0.019, 0.002) 0.122 
Unadjusted 
QALYS 0.988 0.981 
-0.002 
(-0.019, 0.002) 0.563 
Adjusted QALY1 0.023 0.025 0.002 (-0.008, 0.005) 
0.594 
 
 
Appendix 9 Base case and sensitivity analysis for the primary cost 
effectiveness analysis (incremental cost per acceptable hearing resolution at 
12 months) limited societal costs 
Parameter  Incremental 
cost (£) 
Incremental 
effect 
ICER (cost (£) per 
additional hearing 
resolution) 
BASE CASE 
 
160 
 
5.8% £2,759 per additional hearing resolution 
Upper 95% bound1 of net 
cost 500 17.2% 
£2,907 cost per 
additional hearing 
resolution Upper 95% bound
1 of % 
successful hearing resolution 
Upper 95% bound1 of net 
cost 500 -5.5% 
Oral steroid 
dominated by 
placebo Lower 95% bound
1 of % 
successful hearing resolution  
Lower 95% bound1 of net 
cost -181 17.2% Oral steroid dominates placebo Upper 95% bound1 of % 
successful hearing resolution 
Lower 95% bound1 of net 
cost 
Lower 95% bound1 of % 
successful hearing resolution 
-181 -5.5% 
£3,291 saved per 
reduction in 
adequate hearing 
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Appendix 10 Results from the base case and sensitivity analysis for the 
primary cost-utility analysis (incremental cost per QALY gain at 12 
months) limited societal costs 
 
Parameter  Incremental 
cost  (£) 
Incremental 
effect 
ICER 
BASE CASE (values using 
multiple imputed costs and 
QALYs) 
114 -0.015 
Steroid treatment 
dominated by 
placebo 
Upper 95% bound of net 
cost1 406 0.024 £ 16,917 Upper 95% bound of QALY 
gain1 
Upper 95% bound of net 
cost1 406 -0.054 
Steroid treatment 
dominated by 
placebo Lower 95% bound of  QALY gain1 
Lower 95% bound of net 
cost1 -178 0.024 Steroid treatment dominates placebo Upper 95% bound QALY 
gain1 
Lower 95% bound of net 
cost1 -178 -0.054 
£3,296 saved per 
QALY lost 
 
 
 
 
 
